 
Document Type:  Clinical Study Protocol  
Official Title:  Multicenter, single -blind, adaptive dose finding study of 
single intravenous injections of BAY 1747846 with 
corresponding blinded read in adult participants with known or highly suspected CNS lesions referred  for contrast-
enhanced MRI of the CNS 
Study ID: [REMOVED] 
Document D ate: 06-Jan-2022 
 
C O N FI D E N TI A L I nte grate d Cli nical St u d y Pr ot oc ol 
BA Y 1 7 4 7 8 4 6 / 2 0 2 4 1 
0 6 J A N 2 0 2 2 Pa ge:  1of 7 5 
Title P a ge 
Pr ot oc ol Title: 
M ultice nter, si n gle -bli n d, a da pti ve d ose fi n di n g st u dy of si n gle i ntra ve n o us i njecti o ns of 
B A Y 1 7 4 7 8 4 6 wit h c orres p o n di n g bli n de d rea d i n a d u lt pa rtic i pa nts wit h k n o w n or hi g hl y 
s us pecte d C N S lesi o ns referre d f or c o ntrast -e n ha nce d M RI of t he C N S 
Pr ot oc ol N u m ber: 2 0 2 4 1 
Versi o n N u m ber: 5. 0 
A m e n d me nt N u m ber: 4
C o m p o u n d N u m ber: B A Y 1 7 4 7 8 4 6 
St u d y P h ase: 2
S h ort Title: A da pti ve d ose fi n di n g st u d y 
S p o ns o r N a me: Ba ye r A G 
Le g al Re gistere d A d dress: 
N o n -U S: Ba y er A G, 5 1 3 6 8 L e ver k use n, Ger ma n y 
U S territ or y : Ba y er Healt h Care P har mace uticals I nc., 1 0 0 Ba y er B o ule var d, P. O. B o x 9 1 5, 
W hi p pa n y  NJ 0 7 9 8 1 -0 9 1 5, U S A 
Re g ul at or y A ge nc y I de ntifier N u m ber(s): 
E u dra C T: 2 0 1 9- 0 0 1 5 6 0- 3 0 
Pr ot oc ol D ate: 0 6 J A N 2 0 2 2 
Me dical M o nit or na me a n d c o ntact i nf or mati o n will be pr o vi de d se paratel y. 
Na me: M D M S R ole: 
T his is a n electr o nicall y  ge nerate d d oc u me nt t hat d oes n ot bear a n y s p o ns or si g nat ures. T he 
si g nat ure of t he s p o ns or’s me dicall y  res p o nsi ble pers o n i s file d i n t he T M F a n d a vaila ble o n 
re q uest. 
C o nfi de nti al 
T he i nf or mati o n pr o vi de d i n t his d oc u me nt is strictl y c o nfi de ntial a n d is i nte n de d s olel y f or t he perf or ma nce of  
t he cli nical i n vesti gati o n. Re pr o d ucti o n or discl os ure of t his d oc u me nt, w het her i n part or i n f ull, t o parties n ot 
ass ociate d wit h t he cli nical i n vesti gati o n or its use f or a n y ot her p ur p ose w it h o ut t he pri or writte n c o nse nt o f t he 
s p o ns or is n ot per mi tte d. 
T hr o u g h o ut t his d oc u me nt, s y m b ols i n dicati n g pr o prietar y na mes ( ®, T M) ma y n ot be dis pla ye d. He nce, t he 
a p peara nce of pr o d uct na mes wit h o ut t hese s y m b ols d oes n ot i m pl y t hat t hese na mes are n ot pr otecte d. P P D P P D 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  2of 75
Document History Table 
DOCUMENT HISTORY
Document Version Date Comments (if applicable)
Amendm ent 4 5.0 06JAN 2022
Amendm ent 3 4.0 29JUL 2021
Amendm ent 2 3.0 15 OCT 2020
Amendm ent 1 2.0 12 FEB 2020
Clinical Study Protocol 1.0 24 OCT 2019 Version submitted to the HAs
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  3of 75
Protocol Amendment Summary of Changes Table
Amendment 4 ( 06 JAN 2022)
This is a global amendment and is considered to be substantial based on the criteria set forth 
in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.
Overall Rationale for the Amendment:
This amendment was primarily implemented to fulfi ll the FDA request to add secondary  
endpoints to the study  and clarify  the algorithm for dose decision. In addition, e ditorial, 
administrative, and ty pographical corrections were made that do not affect the overall 
document. These changes are not described in this section. The description of change sand a 
brief rationale for each change are as follows:
Section # 
and NameDescription of Change Brief Rationale
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  4of 75
Section # 
and NameDescription of Change Brief Rationale
1.1Synopsis
3.0 Objectives and Endpoints 
8.1.3 Secondary Endpoints
8.1.3.1 Lesion Visualization 
Parameters
8.1.3.2 Number of lesions
9.4 Statistical Analyses 
9.4.1 Efficacy Analyses 
9.4.1.2.1 Lesion Visualization 
Parameters at 5 min post 
injection 
9.4.1.2.2 Lesion visualization 
parameters (border delineation, 
contrast enhancement, internal 
morphology) on pre-contrast 
and combined pre -and post -
contrast (5 min pi) images
9.4.1.2.3 Number of Lesions
9.4.1.3.2 Number of Enhanced 
Lesions on Post -Contrast 
Images at 5 min Post InjectionThe following secondary objective and 
corresponding endpoints were 
implemented: 
Secondary Objective:  
 Compare pre -and post -contrast 
images with respect to lesion 
visualization parameters and 
number of lesions
Corresponding Secondary Endpoints: 
 Lesion visualization parameters 
(border delineation, 
contrast enhancement, internal 
morphology) on pre -contrast and 
combined pre -and post -contrast
(5 min pi) images
 Number of lesions on 
pre-contrast and combined pre-
and post -contrast (5 min pi) 
images
The identified subsections under Sections 
8 and 9 were revised to accommodate the 
analyses of visualization parameters, lesion 
number and statistical variables 
corresponding with the additional 
secondary objective and endpoints.As per FDA request, the study protocol 
was modified to facilitate a secondary 
analysis comparing lesion visualization 
parameters (border delineation, contrast 
enhancement, and internal morphology) 
and number of lesions between pre -
contrast and combined pre- and 
post-contrast images. 
4.3Justification of Dose 
9.2Sample Size Determination In case “Prefer gadobutrol” and Prefer
BAY 1747846” are equally balanced in 
favor of both compounds, dose adjustment 
will not be needed.Clarification for the dose decision 
algorithm (option 2-no dose 
adjustment) to rely solely on the 
primary endpoint
9.5Interim AnalysesRevised wording to specify that an interim 
analysis is optional and ‘‘may’’ be 
performed (changed from ‘‘is planned’’).
If performed, it will not affect the blinding 
design of the study.Clarification that the interim analysis is 
not mandatory.
Only participants (and central readers) 
are blinded as per study design and this 
will not be affected by the interim 
analysis, if performed.
6.1 Study Interventions 
AdministeredTable 6-1 was revised to remove mention 
of specific country sourcing, packaging, 
and label procedures. Additional text 
indicating that local requirements for the 
applicable countries will be followed as to 
ensure compliance.Clarification of text to prevent 
confusion of the local country 
requirements used for sourcing, 
packaging and labeling of study 
intervention.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  5of 75
Table of Contents
Title Page ................................ ................................ ................................ ................................ ... 1
Document History Table................................ ................................ ................................ .......... 2
Protocol Ame ndment Summary of Changes Table ................................ ............................... 3
Table of Contents ................................ ................................ ................................ ..................... 5
Table of Tables ................................ ................................ ................................ ......................... 7
Table of Figures................................ ................................ ................................ ........................ 8
1.Protocol Summary ................................ ................................ ................................ ............ 9
1.1 Synopsis ................................ ................................ ................................ ........................... 9
1.2 Schema ................................ ................................ ................................ ........................... 10
1.3 Schedule of Activities (SoA) ................................ ................................ ......................... 12
2. Introduction ................................ ................................ ................................ ..................... 15
2.1 Study  Rationale ................................ ................................ ................................ .............. 15
2.2 Background ................................ ................................ ................................ .................... 15
2.3 Benefit/Risk Assessment ................................ ................................ ............................... 20
3.Objectives and Endpoints ................................ ................................ ............................... 23
4.Study Design ................................ ................................ ................................ .................... 23
4.1 Overall Design ................................ ................................ ................................ ............... 23
4.2 Scientific Rationale for Study  Design ................................ ................................ ........... 24
4.3 Justification for Dose ................................ ................................ ................................ ..... 24
4.4 End of Study  Definition ................................ ................................ ................................ . 25
5.Study Population ................................ ................................ ................................ ............. 26
5.1 Inclusion Criteria ................................ ................................ ................................ ........... 26
5.2 Exclus ion Criteria ................................ ................................ ................................ .......... 27
5.3 Lifesty le Considerations ................................ ................................ ................................ 29
5.3.1 Meals and Dietary  Restrictions ................................ ................................ .................. 29
5.3.2 Activity ................................ ................................ ................................ ....................... 29
5.4 Screen Failures ................................ ................................ ................................ ............... 29
6.Study Intervention ................................ ................................ ................................ .......... 29
6.1 Study  Interventions Administered ................................ ................................ ................. 29
6.2 Preparation/Handling/Storage/Accountability ................................ ............................... 31
6.3 Measures to Minimize Bias: Randomization and Blinding ................................ ........... 31
6.4 Study  Intervention Compliance ................................ ................................ ..................... 31
6.5 Prior and Concomitant Therap y................................ ................................ ..................... 31
6.6 Dose Modification ................................ ................................ ................................ ......... 32
6.7 Interven tion after the End of the Study ................................ ................................ .......... 32
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ .......................... 32
7.1 Discontinuation of Study I ntervention ................................ ................................ ........... 32
7.2 Dropout ................................ ................................ ................................ .......................... 32
7.3 Participant Discontinuation/Withdrawal from the Study ................................ ............... 32
7.4 Lost to Follow -up........................................................................................................... 33
8.Study Assessments and Procedures ................................ ................................ ............... 33
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  6of 75
8.1 Efficacy  Assessments ................................ ................................ ................................ .... 34
8.1.1 MRI  Procedure ................................ ................................ ................................ ........... 34
8.1.1.1 MRI  Equipment....................................................................................................... 34
8.1.1.2 Sequence Parameters for Brain Imaging ................................ ................................ . 34
8.1.1.3 Quality  Assurance of Images ................................ ................................ .................. 36
8.1.1.4 Image Archiving and Copy ing................................ ................................ ................ 37
8.1.2 Primary  Endpoint ................................ ................................ ................................ ........ 37
8.1.3 Secondary  Endpoints ................................ ................................ ................................ .. 37
8.1.3.1 Lesion Visualization Parameters ................................ ................................ ............. 37
8.1.3.2 Number of lesions ................................ ................................ ................................ ... 38
8.1.4 Other Endpoints ................................ ................................ ................................ .......... 38
8.1.4.1 Quantitative Signal Intensity ................................ ................................ ................... 38
8.1.4.2 Efficacy  Evaluation at 10 and 15 min Post I njection ................................ .............. 38
8.1.4.3 Number of Enhanced Lesions ................................ ................................ ................. 39
8.2 Safety  Assessments ................................ ................................ ................................ ........ 39
8.2.1 Physical Examinations ................................ ................................ ................................ 39
8.2.2 Vital Signs ................................ ................................ ................................ .................. 39
8.2.3 Electrocardiogram ................................ ................................ ................................ ...... 40
8.2.4 Pulse Oximetry ................................ ................................ ................................ ........... 40
8.2.5 Short Mental Status Check ................................ ................................ ......................... 40
8.2.6 Clinical Safety  Laboratory  Assessments ................................ ................................ .... 40
8.3 Adverse Events and Serious Adverse Events ................................ ................................ 41
8.3.1 Time Period and Frequency  for Collecting AE and SAE I nformation ....................... 41
8.3.2 Method of Detecting AEs and SAEs ................................ ................................ .......... 42
8.3.3 Follow -up of AEs and SAEs ................................ ................................ ...................... 42
8.3.4 Regulatory  Reporting Requirements for SAEs ................................ .......................... 42
8.3.5 Pregnancy ................................ ................................ ................................ ................... 43
8.3.6 Adverse Event of Special Safety  Interest ................................ ................................ ... 43
8.3.7 Expected Adverse Events ................................ ................................ ........................... 43
8.3.8 Reporting of Medical Device Failures (Japan Only )................................ .................. 44
8.4 Treatment of Overdose ................................ ................................ ................................ .. 44
8.5 Pharmacokinetics ................................ ................................ ................................ ........... 44
8.5.1 Drug Measurements ................................ ................................ ................................ .... 44
8.5.2 Popu lation Pharmacokinetic Evaluation ................................ ................................ ..... 45
8.6 Pharmacod ynamics ................................ ................................ ................................ ........ 46
8.7 Genetics ................................ ................................ ................................ ......................... 46
8.8 Biomarkers ................................ ................................ ................................ ..................... 46
8.9 Medical Resour ce Utilization and Health Economics ................................ ................... 46
8.10 Population Characteristics ................................ ................................ ............................. 46
8.10.1 Demographics ................................ ................................ ................................ ............. 46
8.10.2 Medical and Surgical History ................................ ................................ ..................... 47
9. Statistical Considerations ................................ ................................ ............................... 47
9.1 Statistical Hy potheses ................................ ................................ ................................ .... 47
9.2 Sample Size Determination ................................ ................................ ........................... 47
9.3 Populations for Analy ses................................ ................................ ............................... 49
9.4 Statistical Analy ses................................ ................................ ................................ ........ 49
9.4.1 Efficacy  Anal yses................................ ................................ ................................ ....... 50
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  7of 75
9.4.1.1 Primary  Efficacy  Anal ysis –Overall Diagnostic Preference at 5 min post 
injection ................................ ................................ ................................ ................... 51
9.4.1.2 Secondary  Efficacy  Analy sis................................ ................................ .................. 52
9.4.1.3 Other Efficacy  Anal ysis................................ ................................ .......................... 53
9.4.2 Safety  Anal yses................................ ................................ ................................ .......... 55
9.4.2.1 Adverse Events ................................ ................................ ................................ ........ 55
9.4.2.2 Other Safet y Examinations ................................ ................................ ...................... 55
9.4.2.3 Demographic and Other Baseline Characteristics Analy ses................................ ... 56
9.4.3 Analy ses of Gd Plasma Concentration ................................ ................................ ....... 56
9.5 Interim Anal yses................................ ................................ ................................ ............ 56
10. Supporting Documentation and Operational Considerations ................................ .... 57
10.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................ 57
10.1.1 Regulatory  and Ethical Considerations ................................ ................................ ...... 57
10.1.2 Financial Disclosure ................................ ................................ ................................ ... 58
10.1.3 Informed Consent Process ................................ ................................ .......................... 58
10.1.4 Data Protection ................................ ................................ ................................ ........... 58
10.1.5 Committees Structure ................................ ................................ ................................ . 59
10.1.6 Dissemination of Clinical Study  Data ................................ ................................ ........ 59
10.1.7 Data Qualit y Assurance ................................ ................................ .............................. 59
10.1.8Source Documents ................................ ................................ ................................ ...... 60
10.1.9 Study  and Site Closure ................................ ................................ ............................... 61
10.1.10 Publication Policy ................................ ................................ ................................ ....... 61
10.2 Appendix 2: Clinical L aboratory  Tests ................................ ................................ .......... 61
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting ................................ ................................ .............................. 63
10.3.1 Definition of AE ................................ ................................ ................................ ......... 63
10.3.2 Definition of SAE ................................ ................................ ................................ ....... 64
10.3.3 Recording and Follow-Up of AE and/or SAE................................ ............................ 65
10.3.4 Reporting of SAEs ................................ ................................ ................................ ...... 67
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy  Information ......... 68
10.5 Appendix 5: Abbreviations................................ ................................ ............................ 69
10.6 Appendix 6: Protocol Amendment History ................................ ................................ ... 72
11.References ................................ ................................ ................................ ........................ 74
Table of Tables
Table 1-1: Study  SoA ................................ ................................ ................................ ............... 13
Table 2-1: Dose normalized AUC and CL /bw (mean [CV%]) obtained from dose groups 1 – 6 
in the FiH Study 19324 for ascending doses of BAY 1747846 in comparison to
the same parameters reported for gadobutrol and gadoterate meglumine ............. 18
Table 6-1: Identit y of study intervention ................................ ................................ .................. 30
Table 8-1: Recommended MRI  sequence parameters ................................ .............................. 36
Table 8-2: Sampling schedule for sparse PK sampling ................................ ............................ 46
Table 9-1: Anal ysis sets ................................ ................................ ................................ ........... 49
Table 10-1: Parameters of laboratory  anal yses................................ ................................ ........ 62
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  8of 75
Table of F igures
Figure 1-1: Overall study design ................................ ................................ .............................. 11
Figure 2-1: RSE (% ± SD) determined in the sigmoidal sinus at 5, 10 and 15 min after 
injection of 0.01, 0.03 or 0.06 mmol Gd/kg bw of BAY 1747846 or 
0.1mmol Gd/kgbw of gadobutrol. ................................ ................................ ....... 19
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  9of 75
1. Protocol Summary
1.1 Synopsis
Protocol Title: Multicente r, single -blind, adaptive dose finding study of single 
intravenous injections of BAY 1747846 with correspo nding blinded 
read in adult participant s with known or highl y suspected CNS lesions 
referred for contrast -enhanced MRI of the CNS
Short Tit le: Adaptive dose finding study
Rationale:
This study  is conducted to establish a dose of BAY 1747846 in pa rticipants with known or 
highl y suspected central nervous s ystem ( CNS )pathology  which shows similar image quality  
and signal enhancement (at a re duced gadolinium [ Gd]dose) to the established comparator 
gadobutrol. Gadobutrol is a macrocy clic gadolinium -based contrast agent (GBCA) approved 
worldwide for various indications and populations (incl. all age groups) with broad utilization 
(more than 50 million administrations [Scott 2018 ]). H ence, it is well suited to serve as 
comparator and to ensure that similar imaging performance can be achieved with 
BAY 1747846 while relevantly  reducing the Gdburden per contrast -enhanced magnetic 
resonance imaging (MRI) examination.
Objectives and Endpoints:
Objectives Endpoints
Primary
Identify a dose for further development 
that has an overall diagnostic preference 
rate simi lar to that of the comparator
gadobutrol at 5min post injection (pi) .Overall diagnostic preference based on a 
randomized paired blinded read using a 5-
point scale (greatly prefer BAY 1747846, 
prefer BAY 1747846, nopreference, 
prefer gadobutrol, greatly prefer 
gadobutrol) at 5 min pi
Secondar y
Show non -inferiority of BAY 1747846 
compared to gadobutrol at 5min pi with 
respect to sum of lesion v isualization 
parameters
Compare pre-and post -contrast images
with respect to lesion visualization 
parameters and number of lesionsLesion visualization parameters 
(border delineation, contrast
enhancement, internal morphology) on 
post-contrast images at 5min pi
Lesion visualization parameters (border 
delineation, contrast enhancement, 
internal morphology) on pre -contrast and 
combined pre- and post -contrast (5 min 
pi)images
Number of lesions on pre- contrast and 
combined pre- and post -contrast (5 min 
pi)images
Overall Design:
This is a multicenter Phase 2 study  with a single -blind design with blinded read in participant s 
with known or highl y suspected CNS pathology. Participa nts will be enrolled in up to 
3cohorts. G adobutrol will serve as active comparator.
Intervention Model:
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  10of 75
Intra -individual comparison, single -blind design
Primary Purpose:
Diagnostic
Number of Arms:
Not applicable.
A maximum of 3 cohorts will be needed for the dose finding of BAY 1747846.
Masking:
Blinded participants , blinded reader s
Number of Participants:
Approximately  60participants per cohort will be assigned to study  intervention such that at 
least 50 evaluable participants per cohort complete the study . Enrolment should continue until 
50 participants have completed t he MRI s in both study  periods and the corresponding 
required images are fully evaluable for efficacy  (i.e. central image qualit y control [ QC] by 
General Clinical I maging Services [GCI S] passed) .If the primary  endpoint is met in the first 
cohort, there will be the option to investigate another cohort with an adapted lower or higher 
dose level to evaluate the robustness and dose range of that result in a no preference outcome 
for BAY 1747846 and the comparator.
In total, a pproximately  180 participants (i.e. if all 3 cohorts will be conducted) will be 
assigned to stud y inte rvention such that at least 150 evaluable participants complete the stud y.
Intervention Groups and Duration:
Each participant will be assigned to receive gadobutrol as intervention for contrast- enhanced 
MRI  as single intravenous (IV) administration during Period 1 and then a single IV 
administration of BAY 1747846 during Period 2.
There will be a washout period of 3 to14days between each study  intervention administration
during the stud y.
The individua l study  duration will be approximately 2 to 4 weeks including screening and last 
measurements in Period 2, which will be conducted 24 h after the last study  MRI . The total 
duration of the study  will be approximately 1yearuntil final clean d ata base .
Data Monitoring Committee:
No
1.2 Schema
This is a multi center, single -blind, ad aptive dose finding study  with corresponding blinded 
read. The first cohort of participants will receive BAY 1747846 at the initial dose of 
0.04 mmol Gd/kg body  weight ( bw). Up to two dose adjustments (in steps of about 
0.005 mmol Gd/kg bw higher or lower) will be performed depending on the outcome of the 
preceding cohort. The active comparator for this study will be gadobutrol (Gadovist /Gadavist ) 
at the approved standard dose for CNS imaging of 0.1 mmol Gd/kg bw . Each cohort will 
consist of at least 50evaluable participants . The overall study  design is shown in Figure 1-1.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  11of 75
Figure 1-1: Overall study design
bw= Body weigh t; Gd = Gadolinium; MRI = Magnetic resonance imaging, N = Number of participants
aDecision on study continuation with a further cohort depends on outcome of previous cohort

CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  12of 75
1.3 Schedule of Activities (SoA)
Table 1-1provides the SoA presenting the study -related measures/actions planned for this 
study . Screening activitie s might be combined with baseline measurements on the same day . 
In that case, the parti cipant needs to sign the informed consent form ( ICF)by documenting 
the time point in addition to the signature date before an y baseline activity  starts. Baseline 
activities are scheduled within 48 h prior to study intervention administration (see Section 
10.1.3 ) and need to be done for each stud y period, including check of inclusion and exclusion 
criteria as relevant changes might occur in between ( e.g. eGFR, medical condition).
The reference point (Day 1, relative time: 00d00 h00min) for the time matrix to be used for 
data evaluation will be the administration of study  intervention. All measures/actions to be 
performed before this reference point will be assigned to negative time points, all 
subsequent measures/actions will have positive time points.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY 1747846 / 20241
06 JAN 2022 Page:  13of 75
Table 1-1: Study SoA
Evaluation/procedure Scr Baselinek MRI and injection phase in
Period 1 and 2Post injection phase in Period 1 and 2
Time point≤48h before 
dosingPrior 
to injectionDosing 5 min piImmediately  after MRI 
(20–60min pi)2 – 4 h 6 – 8 h 24± 4 hm-n
Relative time point -2d 00h 00min0d 00h 00min 
(PRE)0d 00h 
00min0d 00h 05min 0d 00h 20min0d 02h 
00min0d 06h 
00min1d 00h 00min
Written informed consentaX
Demographic data X
Medical/surgical history X
Prior medication X
Concomitant medication X X X X
Urine pregnancy testbX X
Determination of eGFRcX
Body height and weight, BMI X
Complete physical examination X   X X
In/exclusion criteria X X
At-hospitaldX     X
Administration of study  intervention X
Blood pressure, heart rate or pulseeX X X X
Body temperature X X X
Respiratory rate X X
Short physical checkfX
Examination of injection sitegX X X
Short mental status check X X
12-lead ECGeX X X X
Placement of IV line for dosing X
MRI phase Xl X X
Pulse oximetryhX   X
Blood sampling for safety X X X
Blood sampling for PKiX X X X X
Blood sampling for centralized serum 
creatininejX
Urinalysis X X X
AE monitoring X       X
Table continued
CONFIDENTIAL Integrated Clinical Study Protocol
BAY 1747846 / 20241
06 JAN 2022 Page:  14of 75
Table 1-1: Study  SoA –continued
AE = Adverse event; BMI = Body mass index; ECG = Electrocardiogram; eGFR = Estimated glomerular filtration rate; IV = Intravenous; MRI = Magnetic resonance imaging; pi 
= post injection; PK = Pharmacokinetics; Scr = Screening
XMeasure/action to be done at the time point indicated .
Measure/action to be done continuously, starting/ending from/at the time point indicated .
aThe informed consent has to be obtained within 8 weeks before any study -related procedures and assessments are conducted. If screening a nd baseline activities are to 
be performed on the same day, time of signature needs to be documented on the informed consent form in addition to signature date.
bFor women of child-bearing potential only . At the day of study intervention administration, theresult must be available prior to administration of contrast media injection.
cWith regards to baseline of period 1, eGFR can be derived from a serum creatinine result obtained within 4 weeks prior to the first study MRI. If a serum creatinine result is 
not available, it will be determined by the study site (creati nine that is part of blood sampling for safety at each baseline can be used to derive eGFR for the respective 
baseline period as long as the result is available prior to administration of the intervention).
dpatient may be hospitalized throughout each period for participant convenience or site operations, based on operational feasibility, participant health condition and 
willingness, after a positive benefit/risk assessment by the Investigat or for such hospitalization
eAfter 5 min resting phase.
fDone by observation and asking the participant about his/her physical condition.
gBefore and after placement of IV line as well as after discontinuation of IV line.
h Continuously monitored, starting prior to the beginning of the first MRI and continuing throughout until completion of the se cond MRI.
i A second indwelling cannula will be required for PK sampling. Population PK samples time windows: 20 – 60min, 2 – 4h, 6 – 8h and 24 ± 4h (together with blood sample 
for safety) after administration of study intervention. Actual sampling times will be documented in the eCRF. The first 3 time windows will be subdivided in 3 sub-windows, 
see Table 8-2.
jOnly performed once .
kBaseline assessment to be done in Period 1 and 2. All baseline values will be assessed before placement of IV line.
l M RI prior to study intervention administration is an unenhanced MRI (i.e. without contrast media) .Details can be found in Section 8.1.1 .
mIn Period 2, this time point will be the follow -up visit. For participants with premature study termination, the same assessments scheduled for follow -up will be conducted 
during an early discontinuation visit.
n24± 4h procedures for period 1 and/or period 2 may be conducted at hospital, at a local facility or at home based on operational feasibility, local regulations, participant 
health condition and willingness. At hospital procedures arepreferred when possible .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  15of 75
2. Introduction
BAY 1747846 is a new macrocy clic GBCA with high relaxivity for enhancing magnetic 
resonance (MR) images. The clinical utility  of GBCAs in contrast -enhanced MRI  is well 
established and demonstrated in various indications and populations for more than 3 decades 
and in over 500 million procedures.
BAY 1747846 is in development as multi -purpose GBCA for contrast -enhanced MRI in 
adults and children of all ages. So far, i t has been studied in two Phase 1 trials. The initial 
first-in-human (Fi H) study  (Study 19324) examined increasing doses of BAY 1747846, 
ranging from 0.025 up t o 0.2 mmol Gd/kg bw in healthy  men and wome n, and confirmed 
similar safet y and pharmacokinetics (PK) compared to marketed GBCAs. In Study 19325, 
signal enhancement of various selected regions in the head and neck area at increasing dose 
levels (0.01 to 0.06 mmol Gd/kg bw) wa s evaluated in healthy  men and women in comparison 
to gadobutrol at the standard dose of 0.1 mmol Gd/kg bw. Also in this study , the safet y profile 
was similar to gadobutrol and the FiH Stud y 19324. A dose proportional enhancement pattern 
was observed and c ould be compared quantitatively  to gadobutrol.
2.1 Study Rationale
This study  is conducted to establish a dose of BAY 1747846 in participant s with known or 
highl y suspected CNS pathology which shows similar image quality  and signal enhancement 
(at a reduced Gd dose) to the established comparator gadobutrol. Gadobutrol is a macrocy clic 
GBCA approved worldwide for various indications and populations (incl. all age groups) with 
broad utilization ( more than 50 million administrations [ Scott2018 ]). Hence, i t iswell suited 
to serve as comparator and to ensure that similar imaging performance can be achieved with 
BAY 1747846 while relevantly  reducing the Gd burden per contrast -enhanced MRI
examination.
2.2 Background
Since their introduction almost 30 years ago and after 500 million administrations worldwide, 
GBCAs have been established as a crucial element in transforming MRI into a high 
performanc e. GBCAs are complexes of Gd, a paramagnetic metal acting as the signal and 
contrast -enhancing c omponent, with different organic chelators . Depending on the structure 
of the chelator, they  are differentiated in linear or macrocy clic compounds. Macrocy clic 
GBCAs are generally more stable than linear G BCAs.
In 2006, the administration of GBCAs was iden tified as a risk factor for the development of 
Nephrogenic S ystemic Fibrosis (NSF) in patients with severe renal impairment (glo merular 
filtration rate [GFR] <30 mL/min) (Grobner 2006). NSF may  result in fatal or debilitating 
fibros is affecting the skin, muscle, and internal organs. The risk for NSF was found to be 
higher for linear compounds with lower stability  of the Gd- chelate.
In 2014, increased signal intensity (SI)in the dentate nucleus and the globus pallidus was 
reported onunenhanced T1 -weighted (T1 w) MR images in patients who had received multiple 
injections of GBCAs before ( Kanda et al. 2014). Further non -clinical and clinical 
investigations have shown that traces of Gd may  remain in parts of the body , including bone, 
skin, brain, blood, urine, and other areas, for long periods of time after injection of all 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  16of 75
GBCAs. The less stable linear agents resulted in higher concentrations of Gd than the 
macrocy clic agents. In animals, no histopathological c hange was detectable in brain tissue 
after repeated high doses of even the least stable ag ents(Radbruch 2016, Runge 2016) .
Although no s ymptoms or diseases linked to Gd in the brain have been reported, the European 
Medicines Agency  (EMA) took a precautionary  approach, requesting the lowest Gd doses that 
enhance images sufficiently  should be used ( EMA 2017 ).
Health authorities worldwide either requested label updates to reflect the above -mentioned 
findings or requested in the case of the EMA the suspension of the less stable linear 
multipurpose GBCAs as a precautionary  measure. I n addition, health authorities consistently  
request the lowest dose resulting in diagnostic enhancement. BAY 1747846 addresses this 
request b y substantially lowering the Gd burden per administration while maintaining 
sufficient enhancement.
The scientific an d medical evidence to date continues to support a favorable benefit -risk 
profile for GBCAs in the vast majority  of patients, in accordance with the product 
information.
Gadobutrol
Gadobutrol is a macrocyclic GBCA and is indicated for contrast enhancement i n MRI  in 
adults and children for MRI  of the brain and spine, MR angiograph yand whole -body  MRI. 
Clinical safety , efficacy  and PK are well characterized (seelocal product label for 
gadobutrol ).Gadobutrol is approved for various indications in most regions /countries
worldwide including the European Union (EU), USA and Japan.
Preclinical Dataof BAY 1747846
The effect of a GBCA on relaxation times in tissues, and consequentl y enhancement in SIand 
contrast on MR images, depends on its relaxivity  and its conc entration in the tissue of interest, 
i.e. its PK behavior.
For BAY 1747846, the relaxivities measured in vitro were more than 2 -fold higher compared 
to other macrocyclic GBCAs like gadobutrol, when normalized to Gd . MRI  studies in rats, 
rabbits, and minipi gs confirmed that BAY 1747846 shows similar signal enhancement at less 
than half the Gd dose as ot her available macrocy clic GBCAs (see Section 4.1.2 of the 
Investigator’ s Brochure [IB] and rep ortPH-40545 ).
The PK profile of BAY 1747846 was investigated in several animal species, including rats, 
rabbits and c ynomolgus monkeys. It was found to be identical to that of marketed 
multipurpose/ macrocy clic GBCAs with superimposable concentration- time profiles when 
administered at the same dose. Elimination was almost exclusively  via the kidney s and at the 
same excretion rates. The elimination rate of BAY 1747846 was similar to the GFR. In vitro
studies showed a negligible protein binding, no uptake into hepatocy tes and no potential for 
drug-drug interactions. Further details can be found in Section 4.2 of the IB.
Clinical Data of BAY 1747846
First-in-Human (FiH) Study 19324
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  17of 75
The FiH Stud y19324 was a randomized, single -blind, placebo -controlled, escalating single -
dose study  on the safet y, tolerability , and PK of IV administered BAY 1747846 in healthy  
women and men.
The main objective of this study  was to investigate safet y, tolerabilit y and PK includi ng 
gender differences, excretion pathway s and anal ysis for potential metabolites. The first 
3cohorts received single ascending doses of 0.025, 0.05 or 0.1 mmol Gd/kg bw of 
BAY 1747846 orplacebo (0.9% sodium chloride) as a 5 -min IV infusion; cohorts 4, 5 and 
6 received 0.03, 0.1 or 0.2 mmol Gd/kg bw of BAY 1747846 orplacebo (0.9% sodium 
chloride) as IV injection at 2 mL/s. In total, 49participants were recruited in this study  and 
received BAY 1747846 or placebo in Study 19324.
BAY 1747846 was found to be very well tolerated at single IV doses up to 
0.2mmol Gd/kg bw. The safet y assessment based on adverse events (AEs), vital signs, 
electrocardiogra m(ECG) parameters, pulse oximetry , and laboratory  examinations indicate d
that I V administration of BAY 17478 46 was very  well tolerated. The incidence and severit y 
of AEs was independent from the dose administered and similar to placebo. No relevant 
effect son cardiac or respiratory  function w ereobserved. Laboratory  examinations were 
without clinically  relevant observation.
PK results of participants in Study 19324 revealed -as expected -a rapid decline of the 
plasma concentration -time profile shortl y after the end of the administration .Main PK 
parameters (AUC normand CL /bw) are summarized in Table 2-1.
Maximum concentration (C max) was reached shortly after the end of the infusion in most 
cases. Following injection (2 mL/s), C maxwas observed either at 2 or 5 min after injection.
Cmaxand area under the concentration versus time curve (AUC) increased dose proportionally 
from 0.025 to 0.2 mmol Gd/kg bw. The total body  clearance of drug normalized by  bw
(CL/bw), volume of distribution at steady  state normalized by  bw (V ss/bw), mean residence 
time and effective t 1/2remained constant within the dose range tested. BAY 1747846 showed 
a clearance similar to the GFR and V ssindicated distribution into the extracellular water space 
of the bod y.
For the main PK parameters, the variability  was low (between 8.23 and 22.1%). For C max, 
variability  was slightl y higher (up to 34%) as can be expected during the early time after IV 
administration for a compound with such a rapid distribution phase.
As expected a nd similar to other marketed macrocy clic GBCAs, the major part of the Gd dose 
was excreted within 12 h pi. On average, about 84 – 101% of the dose was alread y excreted 
within 12 h via urine, except for the highest dose group, where on average 74% was excre ted 
during that time frame. However, in this group, two participant s had a low recovery  during 
the first 4 h (32 and 57%) post dose which may  indicate loss of urine during collection. 
Exemption of these 2 participants from average calculations showed a rec overy  of 84%.
The PK results of BAY 1747846 were in the expected range based on the preclinical data and 
were very  similar to those reported for marketed macrocyclic GBCAs, e.g. gadobutrol and 
gadoterate meglumine, when corrected for dose.
The CL /bw values determined for all dose levels were around 0.09-0.1 L·kg/h and essentially  
the same as determined for gadobutrol (0.09 L·kg/h) and gadoterate meglumine (0.08 L·kg/h). 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  18of 75
The same holds true for the average dose normalized AUC for all dose groups of 
BAY 17478 46, gadobutrol and gadoterate meglumine, as listed in Table 2-1.
Table 2-1: Dose normalized A UC and CL/bw (mean [CV%]) obtained from dose 
groups 1 –6 in the FiH Study 19324 for ascending doses of BA Y1747846 in 
comparison to the same parameters reported for gadobutrol and gadoterate 
meglumine
Compound / 
administrationDose
[mmol Gd/kg bw]AUCnorm
[kg·h/L]CL/bw
[L·kg/h]
BAY 1747846
5min infusion0.025 10.1 [8.23] 0.0985 (8.23]
BAY 1747846
5min infusion0.05 9.78 [8.51] 0.102 [8.51]
BAY 1747846
5min infusion0.1 10.7 [11.4] 0.0936 [11.4]
BAY 1747846
injection0.03 9.73 [17.2] 0.103 [17.2]
BAY 1747846
injection0.1 10.2 [22.1] 0.0984 [22.1]
BAY 1747846
injection0.2 10.2 [12.0] 0.0978 [12.0]
Gadobutrola
injection0.1 11.1 [N/A] 0.094 [8.90]
Gadoterate meglumineb
injection0.1 9.87 [N/A] 0.08 [12.6]
aReport No. 9746 ; Report No A44213
bLe Mignon et al . 1990; Dotarem SmPC
In addition, the amount of BAY 1747846 excreted within 12 to24h is matching the amount 
of macrocy clic GBCAs (gadobutrol: 86 –100% of the administered dose, se e Report 
No9746; gadoterate meglumine: 89 –95% of the administered dose, see Dotarem Summary  
of Product Characteristics [ SmPC] ) excreted via the kidney s.
Overall, these results confirm the expected safet y and PK of BAY 1747846 that was already  
shown pre -clinically  in several animal species. The determined PK profile, with its rapid 
extracellular distribution and elimination (according to GFR) and its simil arity to other 
marketed macrocy clic GBCAs, supports the implemented minimum washout period of 3 days 
between the administration of BAY 1747846 and gadobutrol, respectively .
Dose -response Study 19325 in healthy  participants
This was a randomized, single- blind, 4 x 4 cross -over, dose -response stud y of 3single IV 
injections of increasing doses of BAY 1747846 compared to gadobutrol in healthy  
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  19of 75
participants. The primary objective of the study  was to determine relative signal enhancement 
(RSE) of BAY 1747846 in r elation to dose and compare it to the RSE achieved with 
gadobutrol at the standard dose (0.1 mmol Gd/kg bw). The secondary  objective of the study  
was to investigate the safety  of BAY 1747846 in healthy  participants.
In this stud y, 43 participant s were trea ted. 42 participant s received 3 doses of BAY 1747846 
(0.01, 0.03 and 0.06 mmol Gd/kg bw) and one dose of gadobutrol (0.1 mmol Gd/kg bw ) in a 
randomized order with at least 7 days between injections.
The conduct of the study  was completed; preliminary  resul ts for safet y and dose response are 
available.
The preliminary  safet y assessment confirmed the good safet y profile observ ed in the FiH 
Study 19324. There were 16participants with treatment -emergent adverse events ( TEAEs), 
12 were of mild and 4 of moderate intensit y. There was a balanced distribution among 
treatments. No AE led to discontinuation and no serious adverse events were observed.
To establish a dose response, SI  was measured in five enhancing areas of the head and neck 
region before (pre) and at approximately  5, 10 and 15 min after each injection: Sagittal sinus, 
sigmoidal sinus, parotid gland, submandibular gland, and internal carotid artery . MR Images 
were acquired with a T1 w3D gradient echo sequence on a 1.5 T MR Scanner. BAY 1747846 
showed an increase in signal enhancement in relation to Gd dose in all regions of interest for 
each imaging time point. RSE for all treatments and time points for an exemplary  area 
(sigmoidal sinus) is shown in Figure 2-1.
Figure 2-1: RSE (% ±SD) determined in the sigmoidal sinus at 5, 10 and 15 min after 
injection of 0.01, 0.03 or 0.06 mmol Gd/kg bw of BAY 1747846 or 0.1 mmol Gd/kg bw 
of gadobutrol.
BAY 1747846: 0.01 mmol Gd/kg bw
BAY 1747846: 0.03 mmol Gd/kg bwBAY 1747846: 0.06 mmol Gd/kg bw
Gadobutrol: 0.1 mmol Gd/kg bw
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  20of 75
RSE for each area was determined b y dividing the difference between pre and post SI  by pre 
SI. Based on the RSE values a dose response curve was established for each area by  inverse 
regression which was then compared to the RSE determined after injection of gadobutrol. 
Overall, BAY 1747846 leads to the same enhancement as gadobutrol with less than half the 
Gd dose. The estimated dose to reach the same signal enhancement was in the range from 
0.038 to 0.065 mmol Gd/kg bw.
These results are well in line with the T1 wrelaxivity  differences of BAY 1747846 
(11.8 Lmmol-1s-1) and gadobutrol (5.2 Lmmol-1s-1), which is approximately 2.3 and 
underline that signal enhancement is independent of different organs and depends mainly  on 
relaxivity  of the GBCA and its presence in the area of interest.
2.3 Benefit/Risk Assessment
This study  will be performed in male and female participants with known or highl y suspected 
CNS pathology . The participants will benefit from the contrast -enhan ced MRI  examination 
which they  will receive based on the underly ing clinical need. They  will not directly  benefit 
from the additional MRI  being performed in relation to the study . However, the data obtained 
from this study  will contribute to the developmen t of BAY 1747846 for contrast -enhanced 
MRI in adults and children of all ages, with the goal to relevantl y reduce the dose of Gd.
The overall safet y profile of GBCAs is favorable and well established with more than 
500million administrations of all GBCAs since 1988. Adverse reactions followi ng their 
administration are usually  mild to moderate in severity  and transient in nature. The most 
commonly  reported adverse reactions following administration of GBCAs are headache, 
nausea and dizziness.
Hypersensitivity /anaphy lactoid reactions consisting primarily  of cutaneous, respiratory , and 
cardiovascular s ymptoms have been recognized to occur in association with all GBCA s. The 
mechanism by  which anaphy lactoid reactions occur is not fully  understood b ut may  involve 
release of active mediators, such as histamine and brad ykinin. The vast majority of 
hypersensitivity  reactions to GBCAs are mild to moderate in nature, and transient, consisting 
of events such as urtica ria and usuall y occur within 30 min aft er administration (Prince et al. 
2011) . As a precaution, hy persensitivity  reactions will be monitored narrowly  as adverse 
event of special safety  interest (AESI) and reported within the same timelin es as any serious 
adverse event (SAE).
Post-marketing experience with GBCAs identified rare adverse reactions, such as 
anaph ylactoid reactions/anaphy lactoid shock, which may  be severe or life -threatening, 
seizures, and NSF as further risks (Prince et al. 2011) .NSF was observed in patients with
severe renal impairment (GFR < 30mL/min) or with acute renal failure, populations excluded 
from participation in this stu dy(Kanal 2016) .
Recently , increased SI was reported in some brain areas on unenhanced scans after repeated 
injections of primarily  linear GBCAs (Kanda et al. 2014) .However, to date, none of the man y 
studies have shown an association between the observed increased SIinthe brain after 
repeated GBCA administrations and the occurrence of an y clinical AEs . Additionally , no 
causal relationship has been reported between clinical signs and s ymptoms and the presence 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  21of 75
of traces of Gd in the body  in patients with normal renal fun ction following use of a GBCA 
(see Section 5.3.3.3 of the IB).
The safet y and tolerability of BAY 1747846 was assessed in the FiH Study 19324 based on 
the incidence and severity of AEs during a stu dy period of 7 days post dose. This included the 
serial evaluation of cardiac (heart rate, blood pressure [BP] , ECG) and respiratory  function 
(peripheral hemoglobin oxy gen saturation ), hematology , biochemistry , and monitoring of 
markers for complement activation and histamine release. In addition, plasma, urine, and 
feces wer e collected over a period of 72 hpost do se to investigate the PK of BAY 1747846, 
including investigation of metabolism and excretion.
No SAE was observed during the study  conduct.
The incidence of TEAE s was similar in all dose g roups and in placebo participant s. Most 
TEAE swere mild, two were of moderate intensit y (creatine kinase increase after intense 
physical activity  and brief ly mphocy te decrease in the context of laboratory evidence of a 
short inflammatory  reactio n) and none were severe. All AEs were recovered or recovering at 
the end of the stud y close out visit one week after administration.
The preliminary  overall safet y assessment based on TEAEs , vital signs, ECG , pulse oximetry , 
and l aboratory  examinations indicates that IV administration of BAY 1747846 was very  well 
tolerated. The incidence and severit y of AEs was independent of the dose administered and 
was similar to placebo. No relevant effect on cardiac or res piratory  function was observed.
Also, no cli nically  relevant change in laboratory  examinations attributable to treatment with 
BAY 1747846 was observed.
Based on nonclinical data and preliminary  data from the FiH Study 19324, the safet y and PK 
profiles of BAY 1747846 are assumed to be similar to othe r GBCAs .
The safet y monitoring activities that are part of this clinical study are considered appropriate 
to detect an y effect with relevance to the safet y of the study particip ants. The principal 
investigator or his/her delegate will be present at the MRI unit from study  intervention 
administration until at least 1 h after administration to promptly  and efficiently  manage an y 
acute reaction, should it occur.
Repeated pregnancy  testing and the required use of highl y effective contraception will 
minimize the risk of inadvertent administration to a pregnant woman or prenatal exposure in 
this study .
Based on the favorable non- clinical and clinical safet y data of BAY 1747846 at the doses 
investigated, it is concluded that female and male participants will not be exposed to any  
relevant health risk in this cross- over stud y. Therefore, their inclusion in this study is justified 
considering the potential benefit that the development of a low- dose, macrocy clic GBCA may  
provide to patients undergoin g contr ast-enhanced MRI examinations.
This clinical study does not involve invasive procedures other than single IV administration 
of the test and comparator GBCAs and a very limited number of venous blood samples for 
safet y and PK anal ysis.
The typical contraindications for MRI  arereflecte d in the selection criteria. When properl y 
performed, the MRI examination is painless and no harmful effects are currentl y known.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  22of 75
In conclusion, the procedure- related risks of study  participation are considered to be minimal.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs ofBAY 1747846 can be found in the IBand for Gadovist/Gadavist within the 
respective local product label .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  23of 75
3. Objectives and Endpoints
Objectives Endpoints
Primary
Identify a dose for further development 
that has an overall diagnostic preference 
rate simi lar to that of the comparator
gadobutrol at 5min piOverall diagnostic preference based on a 
randomized paired blinded read using a 5-
point scale (greatly prefer BAY 1747846 , 
prefer BAY 1747846, nopreference, 
prefer gadobutrol, greatly prefer 
gadobutrol) at 5min pi
Secondary
Show n on-inferiority of BAY 1747846 
compared to gadobutrol at 5min pi with 
respect to sum of lesion visualization 
parameters
Compare pre-and post -contrast images
with respect to lesion visualization 
parameters and number of lesionsLesion visualization parameters 
(border delineation, contrast 
enhancement, internal morphology) on 
post-contrast images at5min pi
Lesion visua lization para meters 
(border delineation, contrast 
enhancement, internal morphology) on 
pre-contrast and combined pre -and post -
contrast (5 min pi) images
Number of lesions on pre -contrast and 
combined pre- and post -contrast (5 min 
pi)images
Other pre -specified
Evaluate SI/enhancement
Evaluate efficacy  at 15 min pi
Evaluate efficacy  at 10 min pi
Determine plasma concentrations of Gd
following administration of BAY 1747846 
and gadobutrol
Evaluate safety profile of BAY 1747846 
in comparison to gadobutrol
Number of enhanced lesions on 
post-contrast imagesQuantitative parameters: SI , contrast to 
noise ratio (CNR), signal to noise ratio 
(SNR)
Lesion visualization parameters at 15 min 
pi
Lesion visualization parameters at 10 min 
pi
Plasma concentrations of Gd within 3 time 
windows o nDay1 and after 24 ± 4h 
following administration of BAY 1747846 
and gadobutrol
Incidence and severity of TEAEs and 
other parameters
Number of enhanced lesions on post -
contrast images at 5 min pi
4. Study Design
4.1 Overall Design
This is a multicenter Phase 2 study  with a single -blind design with blinded read. The study 
will permit up to two adaptive dose changes ( i.e. increase or decrease) to ensure that the dose 
of BAY 1747846 shows similar overall diagnostic prefer enceand enhancement as the 
selected active comparator gadobutrol.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  24of 75
Each participant will receive an IV gadobutrol administration during Period 1 and a n IV 
BAY 1747846 administration during Period 2 followed by  recording of a contrast -enhanced 
MRI in each period .
Between each study  intervention administration there will be a washout period of 3 – 14 days.
The individual study  duration will be approximately  2 to 4 weeks including screening and last 
measurements in Period 2, which will be conducted 24h after the last study  MRI .The total 
duration of the study  will be approximately  1year until final clean data base.
4.2 Scientific Rationale for Study Design
The d ecision for the study  design is primaril y based on the following considerations:
The non- randomized design was selected to enable a diagnostic MRI  for the study  
participants during Period 1 as the parti cipants are patients with CNS lesions requiring 
a contrast -enhanced MRI , and they  need to be provided with standard medical care 
with the first imaging . Therefore, the comparator (gadobutrol) -enhanced MRI  will 
alway s be done in Period 1, whereas the MRI in cluding the injection of BAY 1747846 
will be done during Period 2. Based on the gadobutrol- enhanced MRI, the investigator 
may identify  the need for immediate treatment or that the participant has no lesions, 
both may  yield in exclusion from further study  participation.
The single -blind design is addressing primaril y an unbiased assessment of safet y 
parameters. The stud y participants will be blinded to the study intervention. Only the 
investigator and site staff will be unblinded to the study  intervention, o beying to the 
need for participants to receive the best medical care as urgentl y as needed based on 
clinical judgment.
The single -blind design might potentially  lead to a bias with regard to safety  
assessment on the investigators side. Safet y bias is minim ized by  the blind in the 
participants and evaluation of images for efficacy. The risk for bias was evaluated vs. 
the benefit for the participants in obtaining a diagnostic MRI  in the study  Period 1 and 
was regarded acceptable.
The efficacy anal ysis is done in an independent blinded read which is unaffected by  
the single -blind non -randomized study  design.
4.3 Justification for Dose
BAY 17147846
The starting dose of BAY 1747846 of 0.04 mmol Gd/kg bw wasselected based on the results 
of the dose response Study 193 25.Based on the RSE values determined in five different areas 
of the head and neck, a dose response curve was established for each area by inverse 
regression which was then compared to the RSE determined after injection of gadobutrol. 
Overall, BAY 1747846 le d to the same enhancement as gadobutrol with less than half the Gd 
dose. The estimated dose to reach the same signal enhancement was in the range of 
0.038 to0.065 mmol Gd/kg bw (see Section 2.2). A starting dose was chosen at the lower end 
of the range.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  25of 75
The primary  and secondary  endpoint swill be based on the images acquired 5 min pi, as this 
time point is representative of stead y-state when the GBCA has been distributed in the 
extracellular space. In addition, 5 min pi image acquisition is used broadly in clinical routine 
for CNS contrast -enhanced MRI .
There are 3 possible outcomes from the first coho rt of at leas t 50evaluable participant s (see 
Section9.2for determination of sample size):
1)If the confidence intervals (CI s) for the choices “Prefer gadobutrol” and “Prefer 
BAY 1747846” are not overlapping and the proportion expressing “Prefer gadobutrol” 
is greater than the proportion “Prefer BAY 1747846”, then the dose needs to be 
adjusted upward and an additional cohort with a higher dose willbe enrolled.
2)In case , the choices “Prefer gadobutrol” and “P refer BAY 1747846” are equally  
balanced in favor of both compounds, dose adjustment will not be needed. 
3)If the CIs for the choices “Prefer gad obutrol” and “Prefer BAY 1747846” are not 
overlapping and the pr oportion expressing “Prefer BAY 1747846” is greater than the 
proportion “Prefer gadobutrol”, then the dose needs to be adjusted downward and an 
additional cohort with a lower dose willbe enrolled.
For outcome 1, a second participant cohort will be studied with an adjusted dose of
BAY 1747846 which will be about 0.005 mmol Gd/kg bw higher than the initial dose. I f that 
cohort does not result in outcome 2 or 3, an addi tional dose adjustment of about 
0.005 mmol Gd/kg bw will be performed in a third co hort of additional 50evaluable 
participant s.
The starting dose was selected to be unlikel y to require more than one upwards dose 
adjustment.
For outcome 2, which means that the primary  endpoint is met, there will be noinvestigat ion 
ofanother cohort.
For outcome 3, one downward adjustment of about 0.005 mmol Gd/kg bw with additional 
50evaluable participant s will be performed.
The final determination of the dose will also consider the individual vis ualization parameters 
which are evaluated as secondary  endpoints as well as quantitative SI measurements using 
dedicated software.
Gadobutrol
Gadobutrol will be the active comparator for this study . It will be administered at the 
approve d standard dose for CNS imaging of 0.1 mmol Gd/kgbw.
4.4 End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study  including completio n of the 24 h post MRI  measurement sin Period 2.
The end of the stud y is defined as the date when the clean database is available.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  26of 75
Primary completion
The primary  completion event for this study  is the availability  of the blinded read result s for 
all participants.
5. Study Population
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers o r exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age
1. Participant must be at least 18years of age at the time of signing the informed 
consent.
Type of Participant and Disease Characteristics
2.Known or highly  suspected CNS pathology  (contrast -enhancing CNS lesion) referred 
for contrast -enhanced MRI  of the CNS .The suspicion of a CNS pathology  can be
based on current clinical sy mptoms and/or on a previou s imaging pr ocedure. Ty pes of 
CNS lesions and pathologies which could be included are:
Glial tumor (low grade [I/II], high grade [III/ IV], grade cannot be 
determ ined)
Oligodendrogliomas grade II and III (anaplastic/malignant)
Metastases
CNS ly mphoma
Meningiomas, anaplastic/malignant meningiomas, meningeal spread of 
meningiomas [dural involvement], swannomas, neu rinomas/accusticus 
neurinomas
Craniophary ngiomas
Ependy momas.
Participants who are referred for follow- up MRIs after treatment or for treatment 
planning (e.g. targeted radiosurgery ) are eligible ifthere is a possibility  to schedule an 
additional MRI  exam.
Sex
3.Male and female .
4.Contraceptive use b y men or women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies. 
Sexually  active men , who have not been surgically  sterilized, and women of child-
bearing potential must agree to use relia ble and acceptable methods of contraception. 
This applies for the time period between signing the informed consent form ( ICF), 
until 24 h after the last study  MRI . Men must not to act as sperm donor. Acceptable 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  27of 75
methods of contraception include user -indepen dent (e.g. implantable hormonal 
contraception associated with inhibition of ovulation, intrauterine device, intrauterine 
hormone -releasing s ystem, bilateral tubal occlusion) and user-de pendent methods 
(e.g., hormonal contraception with inhibition of ovulat ion, vasectomized partner if 
sole sexual partner, sexual abstinence). Preference should be given to user -
independent methods of contraception (detailed guidance see Section 10.4).
Informed Consent
5.Capable of giving informed consent within 8 weeks before an y study -related 
procedures and assessments are conducted as described in Section 10.1.3 which 
includes compliance with the requirements and restrictions listed in the ICF and in this 
protocol .
Other
6.Estimated glomerular filtration rate (eGFR) value ≥60mL/min/1.73m2at baseline . 
With regards to baseline of period 1, eGFR value can be derived from a serum 
creatinine result within 4 weeks prior to the first study  MRIdetermined by  local 
hospital lab.
7.Ability  and willingness to understand and follow st udy-related instructions, including 
two contrast-enhanced MRI examination swith both BAY 1747846 and gadobutrol .
8. Confirmation of the participant’s health insurance coverage prior to the baseline 
examinations, if required by  country  (e.g. Germany ).
5.2 Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Considered clinicall y unstable or has a concomitant /intercurrent condition (e.g.
COVID -19 infection) that would not allow participation for the full planned study  
period (i.e. period 1, 2 or both) in the judgement of the investigator .
2.Severe cardiovascular disease (e.g. known long QT sy ndrome, acute m yocardial 
infarction [<14 days], unstable angina, congestive heart failure New York Heart 
Association class IV or acute stroke [<48 h] ).
3.Patients undergoing liver transplantation.
4.Any contraindication to MRI  examinations (e.g. metallic implants, pacema ker, 
claustrophobia) .
5.History  of severe allergic or anaphy lactic/anaph ylactoid reaction to an y allergen 
including drugs and contrast agents, foods, chemicals or other substances .
6.History  of allergic asthma and/ or atopic dermatitis.
7.Suspected lesions or s uffering from an y of the following CNS diseases/l esion ty pesas 
the main indication for MRI . Secondary  findings identified by the investigator might 
not lead to exclusion of the participant, e.g. a small venous angioma :
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  28of 75
Lepto -meningeal disease (e.g. leptomeningeal carcinomatosis ). Dural 
lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded.
Pituitary  adenomas (macro and micro)
Tumors of the choroid plexus
Tumors of the pineal gland
Dermoid/ epidermoid tumors
Infectious disease (e.g. brain abscess, cisticercosis, etc.)
Venous angiomas
Subacute/chronic ischemia
Encephalitis
Multiple sclerosis (acute and chronic)
Optic neuritis
Chordomas
Von Hippel L indau sy ndrome 
Hypertensive leukoencephalopathy .
Prior/Concomitant Therapy
8.Receipt of an y contrast agent <72 h prior to t he study  MRIs, or planned receipt of an y 
contrast agent within 72 h after the second stud y MRI .
9.Planned or expected biopsy  in the region of interest or any  interventional therapeutic 
procedure from the first study MRI up to 24 h after the second stud y MRI.
10. Planned or expected change in any treatment or procedure between the two study 
MRI s that may  alter image comparability , e.g. corticosteroid and /or chemotherapy  
which is changed between the two MRI  procedures.
Prior/Concurrent Clinical Study Experience
11.Has been pr eviousl y enrolled in this study .
12.Has received an y investigational product within 30 day s, or within 5 times half -life of 
the investigational product, whichever is shorter, prior to enrolling in this study .Note: 
Participants who have entered the follow -up period of or have been discontinued from 
an investigational stud y may participate as long as it has been 30 day s after the last 
dose of the previous investigational product , or 5 times half -life of th atinvestigational
product, whichever is shor ter.
13. Contraindications to the admin istration of gadobutrol, as specified in the local product 
label ( e.g. history  of severe hy persensitivity  reaction to gadobutrol).
Other Exclusions
14.Women of child- bearing potential with a positive urine test at the day  of study  
intervention administration.
15.Breast feeding women.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  29of 75
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
Fasting is re commended according to clinical practice .
No water is allowed from 1 h prior to and until 1h afte r study  intervention administ ration.
5.3.2 Activity
Particip ants will abstain from excessive or unusual exercise in the perio d from signing of the 
ICF unt il 24 h a fter the last study  MRI .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  receiving study  intervention. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography , 
screen failure details, eligibility  criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure ) may  be 
re-screened. A maximum of 10% of participants may  beenrolled in the study  after re -
screening. Re-screened participants should be assigned a new participant number. The 
previous participant number of the participant will be documented in the electronic case report 
form ( eCRF).
Re-starting the defined set of screening procedures to enable the “screen failure” to participate 
at a later time point is not allowed –with the following exceptions:
The participant had successfully  passed the screening procedures but could not start 
subsequent study  intervention administration on schedule.
The in-/exclusion criteria preventing the participant’s initial attempt to take part in the 
study  have been changed (via protocol amendment).
In an y case, the invest igator has to ensure that the repeated screening procedures do not 
expose the participant to an unjustif iable health risk. Also, for re -screening, the participant has 
to re-sign the ICF, even if it was not changed after the participant’s previous screening .
6. Study Intervention
Study  intervention is defined as any  investigational interventions, marketed products, placebo, 
or medical devices intended to be administered to a study  participant according to the study  
protocol.
Note: I n this study , study intervent ion refers to administration of test intervention 
BAY 1747846 and comparator intervention gadobutrol.
6.1 Study Interventions Administered
Regarding the selection of doses in the study , refer to Section 4.3.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  30of 75
The identity  ofthe study  interventions is described in detail in Table 6-1.
Table 6-1: Identity of study intervention
Arm name Active drug Active drug
Intervention Name BAY 1747846 Gadobutrol
Type Test drug Comparator drug
Dose formulation Solution for IV injection Solution for IV injection
Unit dose strength 193.43 mg BAY 1747846/mL
(equivalent to 0.3 mmol Gd/mL); 
4ml (773.70 mg) per vial (nominal 
amount)604.72 mg gadobutrol/mL)
(equivalent to 1.0 mmol Gd/mL)
Dosage level(s) 1. coh ort: 0.04 mmol Gd/kg bw
2. cohort: 0.04 +0.005 or 
0.04 -0.005 mmol Gd/kg bw
3. cohort: 0.04 +0.01 or 
0.04 -0.01 mmol Gd/kg bw0.1mmol Gd/kg bw
Route of administration IV injection IV injection
IMP and NIMP IMP IMP
Sourcing Provided centrally by the sponsor Provided locally by the study site as 
marketed product or p rovided
centrally by the sponsor (depending 
on local requirements) .
Packaging and 
LabelingWill be supplied in 10 mL vials, 
colorless glass type I for injection 
with stopper. Each glass vial will be 
labeled as required per country 
requirement.Will be supplied in vials. Study  
intervention will be used as 
unchanged product with market 
authorization oreach vial will be 
labeled as required per country 
requirement (depending on local 
requirement ).
Current/Former 
Name(s) or A lias(es)BAY 1747846 Gadovist/ Gadavist
bw = body weight; Gd = gadolinium; IMP = in vestigational medicinal product ;IV = intravenous;
NIMP = non -investigational medicinal product
Administration procedure
An IV injection line consisting of a large bore indwelling catheter will be placed in an 
antecubital vein. The location of the IV i njection line ha sto be documented in the eCRF.
The study  intervention will be administered as a bolus at the rate of 2 mL/seither using a n 
automated MR -compatible inject ion system or b y hand injection viathe IV injection line , 
each followed by  a 20 mL 0.9% saline flush at the same flow rate. Dose and volume of study  
intervention will be recorded intheeCRF .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  31of 75
6.2 Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. 
3.All study  intervention must be stored in a secure, environmentally  controlled, and 
monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.
4.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (i .e. receipt, reconciliation, and final disposition records).
6.3 Measures to Minimize Bias: Randomization and Blinding
This is a single -blind study . Participants will remain blinded to the sequence of the study  
intervention throughout the course of the stud y. In order to maintain this blind, the study 
intervention must be prepared without the stud y participant being able to witness it. 
Furthermore, the investigator’s team has to ensure that the participants remain blinded 
throughout the stud y.
Blind readers will not be provided with information on study  intervention throughout the 
course of the stud y.
6.4 Study Intervention Compliance
The IV administration of the study  intervention will be done by  a member of the 
investigator’s team. This person will ascertain and document that the participant receives the 
treatment as planned .
6.5 Prior and Concomitant Therapy
Participants are not to receive any  contrast agent < 72 h pr ior to t he study  MRI s or within 72 h 
after the second stud y MRI (see Section 5.2).
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving within 4 weeks before signing of 
the ICF or receives during the study  must be recorded along with:
Reason for use .
Dates of administration including start and stop dates .
Dosage information including dose and frequency .
The Medical Monitor should be contacted if there are an y questions regarding concomitant or 
prior therap y.
The regular use of contraceptives and the occasional use of paracetamol, aspirin, or i buprofen 
are permitted prior and during the stud y.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  32of 75
Medication other than the study  intervention must not be taken during the study without 
consulting the investigator. Participants will be instructed to not use an y medication without 
consulting the investigator, unless prescribed b y a physician to treat an AE. Participants will 
be instructed to report any used concomitant medication, including herbal remedies or food 
supplements, to the investigator. All concomitant medication is to be recorded in the sourc e 
documentation and the appropriate pages of the eCRF. For concomitant medication 
administered on day s of study  intervention administration each dose will be documented with 
time of administration.
6.6 Dose Modification
See Section 4.3.
6.7 Intervention after the End of the Study
After the end of this study, no further treatment is planned.
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal 
7.1 Discontinuation of Study Intervention 
No further participant will be dosed with BAY 1747846 and the study  findings will be 
evaluated thoroughl y at this point to decide on further progress of the stud y, if one of the 
following occurs:
Occurrence of an y SAE assessed as related to BAY 1747846 which is not in line with 
the safet y profile of current macrocyclic GBCAs .
Occurrence of severe AEs related to BAY 1747846 in mo re than 3 participant s. This 
includes changes of laboratory  parameters qualify ing as severe.
Any relevant information, from this study  or from outside of this study , indicating a 
relevant deterioration of the risk -benefit ratio.
See the SoA (Section 1.3) for data to be collected at the time of intervention discontinuation 
and follow -up and for any further evaluations that need to be completed.
7.2 Dropout
A participant who discontinues study  participation prematurel y for an y reason is defined as a 
“screen failure ” if the participant has not received any  study  intervention (Section 5.4) .
A participant who at the time of premature withdrawal, has received an y study  intervention is 
a “drop out ”.
7.3 Participant Discontinuation/Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon.
At the time of discontinuing f rom the study , if possible, an earl y discontinuation visit 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  33of 75
should be conducted. See SoA for data to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be 
completed.
The participant will be permanent ly discontinued both from the study  intervention and 
from the study  at that time.
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected befor e such a withdrawal of consent.
If, in the investigator’s opinion, continuation of the study  which includes start of 
Period 2 would be harmful to the participant’s well- being the participant will be 
permanentl y discontinued . Participants that suffer a severe h ypersensitivity reaction 
related to gadobutrol during Period 1 of the study , must not be advanced into Period 2 
of the study .
7.4 Lost to Follow -up
A participant will be considered lost to follow- up if he /she fails to return for Period 2 and is 
unab le to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study .
Before a parti cipant is deemed lost to follow -up, the investigator or designee mu st 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact attempts should be documented i n the 
participant’s medical record.
Should the participant continue to be unreachable, he/she will be considered lost to 
follow -up.
8. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (see Section 1.3). 
Protocol waivers or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the partici pant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  34of 75
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for sc reening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (e .g.
blood count) and obtained before signing of the ICF may  be utilized for screening or 
baseline purposes provided the procedures met the protocol -specified criteria and were 
performed within the time frame defined in the SoA.
8.1 Efficacy Assessments
The indepe ndent review and centralized measurements will be planned and conducted by 
GCIS (Bayer). Details on blinded image evaluation and centralized procedures will be 
provided by GCIS in the Image Review Charter. The blinded readers will be experienced 
independent certified radiologist snot affiliated with the imaging facilities and not involved in 
the conduct of the study and/or the recruitment of participants. Prior to the conduct of the 
blinded read, the readers will be trained by  GCIS on the alignment of the a ssessment rules for 
image evaluation.
8.1.1 MRI Procedure
8.1.1.1 MRI Equipment
The MRI  will be performed at MRI units with readily  available emergency and intensive care 
facilities. State of the art 1.5 Tesla MRI scanners that can perform the required pulse 
sequences w ith a dedicated head or head/neck coil will be used. The same scanner, coil and 
MR techniques per participant must be used for both the gadobutrol and BAY 1747846 
contrast -enhanced MRIs.
8.1.1.2 Sequence Parameters for Brain Imaging
Protocol -defined sequences for CNS MRI  will be used to obtain unenhanced and 
contrast -enhanced image pre sentations.
The same parameter setting must be used for unenhanced T1 wimages and for contrast-
enhanced T1 wimages in each participant. The required pulse sequences for BAY 1747846 
and gadobutrol are:
Unenhanced:
Localization sequence for brain according to the study  site’ sstandard
2D T1 wimages of the whole brain (axial)
3D T1 wimages of the whole brain (axial or sagittal, consistent across visits 
per participant)
Contrast -enhanced:
3D T1 wimages of the whole brain (axial or sagittal, consistent to 
unenhanced and across visits per participant), starting 5 min pi.
2D T1wimages of the whole brain (axial ), starting directly  after prior 
sequence at about 10 min pi.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  35of 75
3D T1 wimages of the w hole brain (axial or sagittal, consistent across visits 
per participant ), starting 15 min pi.
General considerations:
The MR Iscanner must NOT be activel y retuned a fter the unenhanced 
sequences.
It is crucial that all imaging parameters are as consistent a s possible 
throughout both image visits of each stud y participant.
Further sequences (e.g. DWI  or T2/FLAIR) can be run for local clinical use, as long as no 
active retuning or shimming is ensured between the mandatory  study  sequences. 
The date and start t ime of the study  intervention injection will be recorded in the eCRF as 
well as a ny deviation from the specified MRI procedures and the reason for it (scanner -related 
problem or participant -related problem) .
The recommended MRI parameters for the mandatory  study  sequences are display ed in 
Table 8-1below.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  36of 75
Table 8-1: Recommended MRI sequence parameters
2D T1 wa3D T1 wa
Plane Axial Sagittal or axialb
Pulse sequence Spin echo (SE) Inversion recover y gradient recall echo
(IR-GRE)c
Patient position Supine Supine
Coil Head/head -neck Head/head -neck
Slice thickness 
(Gap /spacing )≤5mm 
(0mm)1mm (isovoxel)
(0mm)
Frequenc y ≥256 ≥256
Phase ≥256 ≥256
Inplane resolution 1.5x1.5mm 1 x 1 mm
NEX/NSA ≥1 ≥1
Parallel imaging Up to 2x Up to 2x
TR According to site’s standard According to site’s standardd
TE According to site’s standard Minimum valued
TI – According to site’s standardd
Acquisition 2D 3D
Contrast media Unenhanced
Starting about 10 min pi(directly after 
prior sequence)Unenhanced
Starting 5 and 15min pi
2/3D = 2/3 dimensional, IR-GRE = inversion recover ygradient recall echo , NEX = number of 
excitations, NSA = number of acquisitions, pi = post injection, SE=spin echo, T1w= T1-weighted, 
TE = echo time, TI = inversion time, TR = repetition time.
a All parameters must be as consistent as possible across both image visits per participant and 
equivalent for pre -and post -contrast T1 wimages per image visit.
b Either axial or sagittal anatomic orientation can be performed, but must be consistent for both 
image visits and for unenhanced and contrast- enhanced images per study par ticipant.
c Equivalent to MPRAGE = magnetization prepared rapid gradient -echo (Siemens & Hitachi), 
inversion recovery spoiled gradient -echo (IR -SPGR or Fast SPGR with inversion activated or 
BRAVO; GE), 3D turbo field echo (TFE; Philips), or 3D fast field echo (3D Fast FE; Toshiba).
dRecommended TR/TE values based on Ellingson et al .: TR = 2100 msec (Siemens, Hitachi) or 
5to15msec (GE, Philips, Toshiba); TI = 1100 msec (Siemens, Hitachi) or 400 to 450msec (GE, 
Philips, Toshiba).
8.1.1.3 Quality Assurance of Images
The investigator must assure that the MRI image set is of acceptable diagnostic quality .
All image sets will be de- identified and sent to GCI S. GCI S will conduct QCand quality  
assurance (QA) of the MR images.
Further details and guidance for the sites will be provided in the Imaging Manual b y GC IS.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  37of 75
8.1.1.4 Image Archiving and Copying
Once all the stud y-related images ar e acquired, all sets of images and related documents are 
considered to be source data and therefore must be stored on appropriate archival media at the 
site according to local requirements , but at least for 15 years.
8.1.2 Primary Endpoint
To assess the primary  study  endpoint, 3 blinded readers (i.e. blinded to the treatment 
allocation and an y other information on the participant) will independentl y compare the 
following contrast -enhanced image sets of each study  participant in a matched pairs approach:
Contrast -enhanced T1 w(BAY 1747846) 5 min pi
Contrast -enhanced T1 w(gadobutrol) 5min pi .
The gadobutrol and B AY1747846 image sets will be randoml y assigned to either the left 
(image L) or right (image R) position in the image visualization sy stem. Qualitative technical 
efficacy is measured by  the reviewers overall diagnostic preference based on the randomized 
paired blinded read using the following 5- point scale:
1 = greatly prefer image R
2 = prefer image R
3 = no preference
4 = prefer image L
5 = greatl y prefer image L .
8.1.3 Secondary Endpoints
8.1.3.1 Lesion Visualization Parameters
The following 3 lesion visualization parameters will be scored b y the 3 blinded readers for 
assessing the secondary  endpoint “lesion visualization parameters” for each enhanced (5 min 
pi) MR image set separately  (no matched pairs approach) , as well as for assessing the 
secondary  endpoint “lesion visualization parameters ” for comparison of pre -and post -contrast 
images on pre -contrast and combined pre- and post -contrast images (5 min pi) separately  (no 
matched paired approach):
Lesion border delineation (see Section 8.1.3.1 .1)
Degree of lesion contrast enhancement (see Section 8.1.3.1.2 )
Lesion internal morphology  (see Section 8.1.3.1.3 ).
8.1.3.1.1 Lesion Border Delineation
Up to 5 of the largest lesions will be selected and scored b y the blinded readers.
The following 4 -point scale will be used for lesion delineation:
1 = None no or unclear delineation of the lesion boundaries
2 = Moderate some aspects of border delineation covered
3 = Good almost clear, but not complete delineation
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  38of 75
4 = Excellent clear and complete delineation .
8.1.3.1.2 Contrast Enhancement
A total of up to the 5 largest lesions will be selected and scored b y the blinded readers.
The following 4 -point scale will be used for lesi on enhancement:
1 = No lesion is not enhanced
2 = Moderate lesion is weakly  enhanced
3 = Good lesion is clearl y enhanced
4 = Excellent lesion is clearl y and brightly enhanced.
8.1.3.1.3 Internal Morphology
Up to 5 of the largest lesions will be selected and scored by  the blinded readers.
The following 3 -point scale will be used for lesions:
1 = Poor the structure and internal morphology  of the lesion is poorly  visible
2 = Moderate the structure and internal morphology  of the lesion is partially  visible
3 = Good the structure and internal morphology  of the lesion is sufficiently  
visible .
8.1.3.2 Number of lesions
The 3 blinded readers will record the total number of lesions for each pre-contrast and 
combined pre -and post -contrast (5min pi) MR image set separatel y (no matched pairs 
approach) . The upper limit of lesions to be counted is 20.
8.1.4 Other Endpoints
8.1.4.1 Quantitative Signal Intensity
For each image set, one additional blinded reader will perform quantitative measurements on 
unenhanced and contrast- enhanced (5 min pi, 10 min pi, and 1 5min pi) images of both image 
sets for each stud y participant. The following quantitative parameters will be calculated (for 
further details see Section 9.4.1.3 ):
Percentage of lesion enhancement
CNR
SNR .
In addition, an algorithm- based evaluation of weighted mean contrast enhancement may also 
be conduc ted centrally  using dedicated software .
8.1.4.2 Efficacy Evaluation at 10and 15min Post I njection
Efficacy  evaluation as described in Sections 8.1.3 and 8.1.4 (lesions visualization parameters, 
number of lesions and quantitative SI ) will additionally  be performed for enhanced images 
10and 15min pi.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  39of 75
8.1.4.3 Number of Enhanced Lesions
The 3 blinded readers will record the total number of enhanced lesions for each enhanced 
(5min pi) MR image set separately  (no matched pairs approach) . The upper limit of lesions to 
be counted is 20.
8.2 Safety Assessments
Planned time points for all safety assessments are provided in the SoA (Section 1.3).
8.2.1 Physical Examinations
The complete ph ysical examination (by  means of inspection, palpation, auscultation) will be 
performed b y a physician ,or by  another qualified healthcare professional under the 
responsibility  of the investigator or ph ysician designee ,and cover at least the organs of the 
cardiovascular, respiratory and abdominal sy stems. Orientating tests of neurolog ical function 
will be included.
The short ph ysical check will be done by a qualified healthcare professional byobservation 
and asking the participant about his/her phy sical cond ition. Additionally , participants will be 
asked using open questions about an y symptoms that they  experience, i.e. AEs.
The performance of the phy sical examination will be documented in the eCRF. Abnormal 
physical examination findings are recorded either a s medical history  or as AEs (see 
Section 10.3.1 ).
8.2.2 Vital Signs
The follow ing vital signs will be assessed at the time point s specified in the SoA 
(Section 1.3):
BP(systolic and diastolic)
Heart rateor pulse
Body temperature
Respiratory  rate.
BPand heart rate or pulse will be assessed by a member of the investigator’s team under the
following conditions:
Position: S upine (small pillow under head allowed) , resting period of at leas t 5min in 
a quiet setting without distractions (e.g. television, cell phones).
Measuring site: cuff to be placed on the right/left upper arm (if possible, the same arm 
will be used for all measurements in one participant); cuff location will be 
documented. BPwill not be measured at the arm used for injection of the study  
intervention.
Method: oscillometric measurement of s ystolic and diastolic BPby automat ic 
measurement device.
Body temperature will be measured b y a member of the investigator’s team with an 
appropriate thermometer. The location of temperature measurement willbe documented in the 
eCRF.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  40of 75
8.2.3 Electrocardiogram
Single 12-lead ECGs will be obtained as outlined in the SoA (see Section 1.3) by a member of 
the investigator’s team under the following conditions:
Position: supine (small pillow under head allowed) for at least 5 min
Device: computerized ECG device, representing paper velocity  of 25 mm or 50 mm 
per second as preferred by the site, same velocit y for all ECGs
Automatic calculation of the following parameters: Heart rate (HR), PR interval (PR), 
QRS duration, QT interval uncorrected (QT) and corrected for HR (QTc).
Safety  evaluation of all ECG recordings b y a site physician ,in a timel y manner durin g 
the timeframe of the visit, providing diagnosis including an overall assessment of the 
findings and the overall clinical relevance (normal, abnormal clinicall y insignificant or
abnormal clinicall y significant).
All ECGs recorded during the stud y at one site will be evaluated b y a cardiologist 
from the institutions, including measurements of intervals and a diagnosis. Only  these 
ECG measurements will be used for the statistical d ata evaluation.
8.2.4 Pulse Oximetry
In both stud y periods, non- invasive monitoring of pulse oximetry  will be performed during 
the MRI  phase. The continuous assessment will be done while the participant is in the MR
scanner .Results of the pulse oximetry  monitoring will not be recorded within the eCRF 
unless the results qualify  for an AE.
8.2.5 Short Mental Status Check
A short mental status check will be performed, which is an interview of the participants to do 
a basic assessmen t of orientation, memory , and cognitive function , for time points see SoA 
(Section 1.3).
8.2.6 Clinical Safety Laboratory Assessments
Blood and urine samples will be collected by a member of the investigator’s team.  
Detailed information about the collection, processing, storage and shipment of 
laboratory  samples is provided in the laboratory manual .
See Section 10.2 for the list of clinical laboratory tests to be performed and the SoA 
(Section 1.3) for the timing and frequency .
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
eCRF. The laboratory  reports must be filed with the source documents. Clini cally  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  the investigator to be more severe th an expected 
for the participant’ s condition.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  41of 75
Additional safet y assessments may be conducted at the discretion of the investigator. 
These may be laboratory  examinations at additional time points or additional 
laboratory  parameters.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or w ithin 24 h after the las t dose of study  intervention should 
be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator.
If such values do not return to normal/baseline within a period of time 
judged reasonable by the investigator, the etiology should be identified and 
the sponsor notified.
All protocol -required laboratory  assessments, as defined in Section 10.2, 
must be conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values from non- protocol specified laboratory  assessments 
performed at the institution’s local laboratory  require a change in 
participant management or are considered clinically  significant b y the 
investigator (e .g. SAE or AE or dose modification), then the results must be 
recorded in the eCRF.
In the event of implausible results, the laboratory  may  measure additional parameters 
to assess th e quality  of the sample (e.g. clotted or hemoly zed) and to verify the results.
8.3 Adverse Events and Serious Adverse Events
The definitions of an AE or SAE can be found in Section 10.3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y authorized representative or health care professional not involved in the
study ).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE . They remain responsible for 
following up S AEs, or AEs considered related to the study intervent ion or study  procedures, 
orthose that caused the participant to discontinue the study . AESIs have to be followed up 
regardless of causality  or relationship to study  intervention (see Section 8.3.6 ).
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
AllAEs/ SAEs will be collected from signing of the I CF until follow -upat the time points 
specified in the SoA (Section 1.3).
Medical occurrences that begin before the start of study  intervention but after signing the ICF 
will be recorded on the Medical History /Current M edical Conditions sectio n of the e CRF not 
the AE section, if they :
Are surgical procedures that were planned prior to the start of the stud y by any physician 
treating the participant.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  42of 75
Started before signing the I CF and for which no sy mptoms or treatments are present until 
signing of ICF (e.g. seasonal allergy  without acute complaints).
Started before signing of ICF and for which s ymptoms or treatment are present after 
signing ICF at an unchanged intensit y (e.g. allergic pollinosis).
All SAEs will be recorded and reported to the sp onsor or designee immediately  and under no 
circumsta nces should this exceed 24 h, as indicated in Section 10.3. The investigator will 
submit any  updated SAE data to the sponsor within 24 h of it being available.
Investigators are not obligated to activel y seek AE sor SAE safter conclusion of the study  
participation. However, if the investigator learns of an y SAE, including a death, at an y time 
after a partici pant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor.
8.3.2 Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
non-leading verbal questioning of the participant is the preferred method t o inquire about AE 
occurrences.
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is req uired to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and non -serious AESIs (as defined in 
Section 8.3.6 ), will be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow -up (as defined in Section 7.4). Further
information on follow- up procedures is given in Section 10.3.
8.3.4 Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a nSAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (e .g.summary  or listing of SAEs) from the sponsor will 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  43of 75
review and then file it along with the IBand will notify  the IRB/IEC, if appropriate 
according to local requirements.
8.3.5 Pregnancy
Details of all pregnancies i n female participants and, if indicated, femal e partners of 
male participants will be collected after the start of study  intervention and until 24 h
after the second stud y MRIduring Period 2. Any outcome of the mother and the child 
at delivery  should be reported.
If a pregnancy  is reported, the investigator should inform the sponso r within 24 h of 
learning of the pregnancy  and should follow the procedures outlined in Section 10.4.
Abnormal pregnancy  outcomes (e .g.spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered as SAEs.
The child’s health should be followed up until 6 to 8 weeks after birth.
8.3.6 Adverse Event of Special Safety Interest
Any AE SI is to be reported within 24 h of the investigator’s awareness, independentl y from 
seriousness and causality assessments.
For the purpose of this study , the following AEs are defined as AESI :
Reactions indicating h ypersensitivity , e.g. bronchial asthma, rhinosinusitis, 
anaph ylaxis, urticar ial,and any  type of skin reactions including late cutaneous and 
organ -specific reactions.
All AEs which are “severe” in intensity .
Hypersensitivity /anaphy lactoid reactions have been reported to occur rarel y for al l GBCAs, as 
discussed in Section 2.3. The definition of h ypersensitivity /anaph ylactoid reactions as AESI is 
intended as a precaution, to assure that the sponsor is informed within short timeline s about 
their occurrence and to allow thorough investigation of all circumstances, e.g. concomitant 
medications or environmental factors.
SAEs may  represent a stopping criterion for the study  (Section 7.1) and, therefore, need to be 
followed closel y.
8.3.7 Expected Adverse Events
For this study , the applicable reference document is the current version 2.0 of the IBfor 
BAY 1747846 and the SmPC of gadobutrol (available at 
(https://www.medicines.org.uk/emc/product/2876/smpc ).If relevant new safet y information 
for BAY 174784 6 is identified, the information will be int egrated into an update of the IB and 
distributed to all participating stud y centers.
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference document and according to all local regulations.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  44of 75
Expected C onduct -related A dverse Events
The frequent blood sampling (b y single vein puncture and/or indwelling cannula) may  be 
accompanied b y mild pain, hematoma and, in rare cases, inflammation of the vessel wall or 
injury  of a nerve. Awareness should be raised to the possibility  of a vasovagal attack or 
syncope (marked by  pallor, nausea, sweating, brady cardia, decrease in arterial BP , which, 
when below critical level, results in dizziness and/or loss of consciousness) during the 
sampling procedure.
The use of adhesive electrodes (ECG leads) and /or adhesive dressings may  be accompanied 
by mild and transient reddening and/or itching of the skin.
8.3.8 Reporting of Medical Device Failures (Japan Only)
Medical device failure is defined as a medical device event which is related to an SAE or 
could cause he alth damage to participants or healthcare professionals in a clinical study . The 
investigator must report immediately  all non -approved medical device failures. For this 
reporting, the forms provided are to be used and sent to the designated recipient.
8.4 Treatment of Overdose
For this study , any  dose of BAY 1747846 greater than 0.2 mmol Gd/kg bw (corresponding to 
the highest dose applied in the FiH Study 19324) and any  dose of gadobutrol greater than 
0.3mmol Gd/kg bw within a 24 -h time period will be considered an overdose. This dose is 
below the currentl y approved maximum dose for GBCAs. It is assumed that overdosing with 
the study  intervention is highl y unlikely. No signs of intoxication from an overdose of 
gadobutrol have so far been report ed during clinical use ( see local product label of
gadobutrol) .GBCAs like BAY 1747846 and gadobutrol are quickl y eliminated via glomerular 
filtration, which is not- dose depended. Patients with impaired renal functi on will be excluded 
from the study . 
In the event of an overdose , the investigator should:
1. Contact the Medical Monitor immediately .
2. Closely monitor the participant for an y AE/SAE and laboratory  abnormalities 
(cardiovascular monitoring [including ECG] and control of renal function 
recommende d as a measure of precaution) u ntil BAY 1747846 or gadobutrol can no 
longer be detected s ystemically  (at least 7days).
3. Obtain a plasma sample for PK anal ysis withi n 7days from the date of the last dose of 
study  intervention if requested by  the Medical Monitor (determined on a case -by-case 
basis).
4. Document the quantit y of the excess dose in the eCRF.
8.5 Pharmacokinetics
8.5.1 Drug Measurements
In total, 5 blood samples will be collected per participan t per period for measurement of Gd in 
plasma at the time points s pecified in the SoA (Section 1.3).Instructions for the collection 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  45of 75
and handling of biological samples will be provided by the sponsor in the laboratory manual . 
The actual date and time (24 -h clock time) of each sample will be recorded in the eCRF .
Plasma concentrations of Gd will be determined using a valid ated inductivel y coupled plasma 
mass spectrometry  method. Calibration samples and QC samples will be analy zed 
concurrently  with study  samples. The results of calibration and QC samples will be reported 
in the Bioanal ytical Report, which will be included in the Clinica l Study Report for this study .
Whenever possible, all efforts should be made to adhere to the sampling time windows in the 
SoA as it is important to have these data thoroughly  and accuratel y documented in the eCR F.
Sampling times outside the suggested time windows will be listed as “other protocol 
deviations” only .
8.5.2 Population Pharmacokinetic Evaluation
Per period, a baseline blood sample will be taken prior to and 4 blood samples will be taken 
after administration of BAY 1747846 or gadobutrol and after the ima ging MRI  scans are 
complete in all participants. Each blood sample will be drawn dur ing a pre -defined time -
windo w (20min– 1 h, 2 – 4 h, 6 – 8 h after stud y intervention administration) or at 24 ±4h 
after stud y intervention administration. The first time window starts after the MRI  acquisition 
is completed. The 3time windows and the late time point on the following day were chosen 
based on the well- established PK profile of GBCAs and the determined similarity  of the PK 
profile of BAY 1747846 in the FiH S tudy 19324.
The3 time wi ndows on the dosing day  will be subdivided into 3 further sub -windows (see 
Table 8-2). In order to achieve an approximately  equal distribution of blood samples over the 
whole time window, the time points (sub- windows) at which the samples are taken will be 
randomized. This means that the sampling time point for each participant will be allocated to 
a sub -window . The PK sample schedul ed for the next day  (24± 4h) can be taken together 
with the safety blood sample.
The PK calculation will be based on the actual sampling and dosing times. Therefore, it is of 
importance to have this data thoroughly  documented in the eCRF. Deviations from the 
specified time points will be documented and taken into account when calculating the PK 
parameters. Those deviations do not qualify  as protocol violations.
Randomization of the sub -windows will be performed for each participant on the basis of a 
computer -generated randomization list. Each study site will be provided with a randomization 
list for a balanced participant assignment to all sub- windows per time point.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  46of 75
Table 8-2: Sampling schedule for s parse PK sampling
Time window /time frame for blood sampling Sampling times points as defined by 
randomization
Immediately pre -injection Randomization not applicable
20min – 1 h 20minto <30min
30min to <45 min
45min to 1 h
2h – 4 h 2h to < 2 h40min
2 h40min to <3 h 20min
3 h20min to 4 h
6h – 8 h 6h to <6 h40min
6 h40min to <7 h 20min
7 h20min to 8 h
24± 4 h Randomization not applicable
Gd plasma concentration data for BAY 1747846 collected in the present study  will be 
evaluated using non -linear mixed effects models together with data collected from other 
clinical studies investigating BAY 1747846. Mixed effects models, or population -type PK 
models, describe the relationship between dose, time and variables, such as drug plasma 
concentrations. The population PK model to be developed based on PK data from the FiH 
study  data will be applied and adjusted, if appropriate. PK of BAY 1747846 will be compared 
to gadobutrol.
The results of this evaluation may  be presented in a se parate Modelling and Simulation
Evaluation Report.
8.6 Pharmacodynamics
Not applicable .
8.7 Genetics
Not applicable .
8.8 Biomarkers
Not applicable.
8.9 Medical Resource Utilization and Health Economic s
Medical Resource Utilization and Health Economics parameters will not beevaluated in this 
study .
8.10 Population Characteristics
8.10.1 Demographics
For demographic assessment the following parameters will be recorded: year of birth/ age, sex, 
race/ethnicity , weight and height.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  47of 75
Body weight and height, body mass index
Body weight will be measured b y a member of the investigator’s team under the following 
conditions:
Light clothing without shoes after having emptied the bladder.
Electronic ph ysician (column) scale with digital display , measurement units 0.1 kg.
The participant’s height will be measured (without shoes). The body  mass index ( BMI )will 
be calculated in RAVE, see Section 10.1.7 .
8.10.2 Medical and Surgical History
Medical and surgical history  findings (i.e. previous diagnoses, diseases or surgeries) meeting 
all criteria listed below will be collected as available to the investigator:
Not pertaining to the study  indication,
Starting before signing of the I CF,
Considered relevant for the participant’ s study  eligibility .
Detailed instructions on the differentiation between medical history  and AEs can be found in 
Section 10.3.1 .
9. Statistical Considerations 
9.1 Statistical Hypotheses
The main objective of this study  is to identify  a BAY 1747846 dose similar to the comparator
gadobutrol in diagnostic preference . Therefore, only  point estimators and CIs will be 
considered and no formal hy pothesis testing will be pe rformed to compare differences 
between treatments or between individual doses.
9.2 Sample Size Determination
The justification of sample size was based on the proportion of participants for whom “No 
preference”, “Prefer BAY 1747846” and “Prefer gadobutrol” is expressed for each cohort
along with a corresponding two- sided 95% CI .
Number of Participants
For each BAY 1747846 dose cohort, approximately  60 participants will be enrolled. Based on 
the experience from previous studies, it is expected that up to 18% of the participants will 
discontinue prematurel y and thus have images with only  one of the two study  interventions 
available .Therefore, participants will be enrolled on an ongoing basis until 50 participants 
have completed the MRIs in both study  periods to ensure 50 evaluable participants per cohort 
for the analy sis.
A maximum of two dose adjustments will be used, so that a maximum of approximately  
180participants (3 cohorts) will b e enrolled into t he study .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  48of 75
Dose Finding Algorithm
The decision criteria for dose adjustment will consider both the proportion of pa rticipants for 
whom no preference is selected, and the difference between the proportion preferrin g 
gadobutrol and preferring BAY 1747846.The following algorithm for dose adjustment will be 
used:
If the CIs for the choices “Pre fer gadobutrol” and “Prefer BAY 1747846” are not 
overlapping and the proportion expressing “Prefer gadobutrol” is greater than the 
proportion “Prefer BAY 1747846”, then the dose needs to be adjusted upward and an 
additional cohor t with a higher dose will be enrolled.
In case ,the choices “Prefer gadobutrol” and “Prefer BAY 1747846” are equally  
balanced in favor of both compounds, dose adjustment will not be needed. 
If the CIs for the choices “Prefer gadobutrol” and “Prefer BAY 1747846” are not 
overlapping and the proportion expressing “Prefer BAY 1747846” is greater than the 
proportion “Prefer gadobutrol”, then the dose needs to be adjusted downward and an 
additional cohort with a lower dose will be enrolled.
Simulation
The reads of the blinded readers will be treated as independent confirmations of the results. 
For each cohort, 3 readers will be used as independent replications of the result, therefore the 
number of participants is 50 even though there will be 150 reads available. Having 2or 
3 readers giving the same result lends confidence to the conclusion. If 2or 3readers reach the 
same conclusion on the recommended action (no dose adjustment needed, dose increase 
needed, dose decrease needed), then that will be the recommended action taken.
If all 3 readers reach different conclusions, then no dose adjustment is needed.
If 50% of choices are no preference, with 50 evaluable participants the 95% CI  would be 
(36%, 64%). Based on simulations and a ssuming that the true p ercentage of no preference 
responses is 50%, and that there are no differences between the proportions preferring 
BAY 1747846 and comparator, with 50 patients the above decision algorithm would conclude 
no dose adjustment greater than 95% of the time. This is equivalent to saying that with 
50patients and these assumptions there is greater than 95% power to conclude that no dose 
adjustment is needed. If we assume that there is a 30% difference in proportions between 
preferring BAY 1747846 and comparator, there is 77% power to conclude that a dose 
adjustment is needed .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  49of 75
9.3 Populations for Analyses
For purposes of analy sis, the following populations are defined:
Table 9-1: Analysis sets
Population Description
Enrolled All participants who sign the ICF.
Full analy sis set (FAS) All participants who have complete MR image datasets that 
qualif y for blinded read .
Safety analy sis set (SAF) All participants who receive any  dose of study intervention. 
9.4 Statistical Analyses
The statistical anal ysis plan will be developed and finalized before database lock and will 
describe the participant populations to be included in the anal yses, and procedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analy ses of the primary  and secondary  endpoints.
For the primary  objective
The estimand is then the proportion of participants for whom no preference is chosen for 
the image preference in the overall diagnostic preference based on a randomized paired 
blinded read usin g a 5 -point scale (see Section 8.1.2 ) at 5 min pi in all participants who 
have 2image sets (gadobutrol and B AY1747846) available. No imputations or 
adjustments will be made for those participants who have no images or onl y one image set
as these participants will be excluded from the analy sis.
The estimand is then the difference between the proportion of partic ipants for whom the 
BAY 1747846 image sets are preferred and the proportion of participants for whom the 
gadobutrol image sets are preferred in the overall diagnostic preference based on a 
randomized paired blinded read using a 5 -point scale (see Section 8.1.2 ) at5min pi in all 
participants who have 2image sets available. No imputations or adjustments will be made 
for those participants who have no images or onl y one image as these participants will be 
excluded from the analysis.
For the secondary objective s
The estimand is then the sum of lesion visualization parameters between both image sets
(BAY 1747846 and gadobutrol )in all participants who have 2image setsavailable. No 
imputations or adjustments will be made for those participants who have no images or 
only one image set as these participants will be excluded from the analysis.
The estimand is then the mean of lesi on visualization parameters between both image sets
(pre-contrast and combined pre -and post -contrast )in all participants who have 2image
setsavailable. No imputations or adjustments will be made for those participants who 
have no images or onl y one ima ge set as these participants will be excluded from the 
analysis.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  50of 75
For objectives and endpoints see also Section 3.
For the anal ysis of preference, a participant needs to have two image sets (gadobutrol and 
BAY 1747846) available. No imputations for missing data will be performed. A low number 
of missing values will be expected due to the short duration for each participant and the 
expected high adheren ce to the study  protocol. Imputations might introdu ce bias due to the 
small sample size and the study  design (for drop- outs, the experimental intervention will 
alway s be missing).
9.4.1 Efficacy Analyses
Endpoint Statistical A nalysis Methods
Primary
Overall diagnostic preference based on a 
randomized paired blinded read using a 5-
point scale (greatly prefer BAY 1747846, 
prefer BAY 1747846, no preference, prefer 
gadobutrol, greatly prefer gadobutrol) at 5 min 
piFor overall diagnostic preference 95% two -
sided CIs for the proportion of participants for 
whom “No preference ”was expressed will be 
calculated.
Treatment difference will be tested with 
McNemar’s test.
Secondary
Lesion visualization parameters (border 
delineation, contrast enhancement, internal 
morphology) on post -contrast images at 5min 
pi
Lesion visualization parameters (border 
delineation, contrast enhancement, internal 
morphology) on pre -contrast and combined 
pre-and post -contrast (5 min pi) images
Number of lesions on pre -contrast and 
combined pre- and post -contrast (5 min pi)
imagesForthe sum of lesion visualization parameters, 
95% two -sided CIs for the mean difference 
between BAY 1747846 and gadobutrol will be 
calculated .
For lesion visualization parameters, 95% two -
sided CIs for the mean difference between 
pre-contrast and combined pre -and post -
contrast will be calculated.
The number of lesions will be analyzed 
descriptively.
Other pre-specified
Quantitative parameters: SI, contrast to noise 
ratio (CNR), signal to noise ratio (SNR)
Lesion visualization parameters at 15 min pi
Lesion visualization parameters at 10 min pi
Number of enhanced lesions on post -contrast
imagesThe percentage of enhancement of the lesion 
post administration of study intervention 
injection in comparison to baseline (i.e. prior to 
administration of study intervention) will be 
calculated.
Sum of lesion visualization parameters at 
15min pi will be analy zeddescriptively .
Sum of lesion visualization parameters at 
10min pi will be analyzed descriptively.
The number of enhanced lesions will be 
analyzed de scriptively.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  51of 75
9.4.1.1 Primary Efficacy Analys is –Overall Diagnostic Preference at 5min 
post injection
The blinded readers will evaluate the relative image quality  ofthe BAY 1747846 -enhanced
T1wMR images and the gadobutrol -enhanced T1 wMR images. The assessment will be based 
on the overall subjective interpretation of the degree of contrast enhancement, border 
delineation, and internal morphology . These images will be presented in a paired fashion in a 
separate reading session. The BAY 1747846 and gadobutrol images will be randomly  
assigned to either the left (image L) or right (image R) positions.
Image qualit y will be compared on a 5 -point scale:
1 = greatl y prefer image R
2 = prefer image R
3 = no preference
4 = prefer image L
5 = greatl y prefer image L .
As part of the randomization and blinding process, R and L  will represent either the 
BAY 174784 6 or gadobutrol image .After the data is unblinded, the above codes will be 
translated into the following scale:
1 = greatl y prefer BAY 1747846,
2 = prefer BAY 1747846,
3 = no preference
4 = prefer gadobutrol,
5 = greatl y prefer gadobutrol.
For each cohort, the proportion of participants for whom “No preference”, “Prefer 
BAY 1747846” and “Prefer gadobutrol” is expressed, will be calculated along with a
corresponding two- sided 95% CI . The three categories are collapsed from the 5 -point 
preference scale .
Additionally , the distribution of the choices other than “No preference” willbe examined 
descriptivel y using frequency tables and histograms. 
The null and alternative hy potheses for an exploratory  anal ysis of a treatment difference are 
as follows:
  :	       	   	       =       	          	
  			  :	       	   	       ≠       	           ,
where π      	   	        is the proportion of participants for whom the BAY 1747846-
enhanced image was preferred and π      	           is the proportion of participants for 
whom the gadobutrol -enhanced image was preferred. For this exploratory  analysis, a 
McNemar ’s test will be used.
A table display ing frequencies and percentages of the results of the 5 -point scale will also be 
provided.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  52of 75
9.4.1.2 Secondary Efficacy Analysis 
For the secondary  endpoints, there will be multiple values for each subject (ratings for 
multiple lesions). The average of these ratings will be used for the anal yses. To avoid using a 
scoring s ystem that rates the detection of fewer but more well -visualized lesions over the 
detection of more lesions, some of which may  be not so well visualized, the anal ysis will be 
performed using zero -filled averages of the ratings for each subject. A more detailed 
description will be provided in the SAP.
9.4.1.2.1 Lesion Visualization Parameters at 5min Post Injection on Post-
Contrast I mages
The 3 analysis variables are derived from the 3 parameters below using the following 
methodology :
1. C ontrast enhancement (measur ed on an ordinal 4- point scale)
2. B order delineation (measured on an ordinal 4 -point scale)
3. Internal morphology  (measured on an ordinal 3- point scale).
In order to reduce multiplicity , the 3 variables will be combined b y adding them up for each 
participant and each blinded reader, leading to only  one variable on an ordinal 11- point scale.
Average reader will be used in addition to the 3 individual readers.
The anal ysis is based on the data from the blinded readers’ evaluation of the 3 visualization 
parameters, which are evaluated in the MR image sets.
For the comb ined visualization parameter, the non -inferiorit y of BAY 1747846 versus 
gadobutrol will also be evaluated using CIs based on the t- distribution. A non- inferiorit y 
margin of 1 will be used.
The non- inferiority  margin was determined by  the 95% -95% method described in the FDA 
Guidance “Non -Inferiority  Clinical Trials to Establish Effectiveness” and is based on th e past 
performanc e of the comparator in the Gadavist Study 310123 . Data from this stu dywere re-
analyzed using the combined approach described above. After combining the visualization 
parameters of Study 310123 and calculating the two -sided 95% CI for the mean difference 
gadobutrol – unenhanced ,the observed mean difference was 2.49 and the corresponding 95% 
CI [2.337; 2.651]. As described in the FDA Guidance, the lower bound of the 95% CI was 
selected as the known effect of gadobutrol to the unenhanced imaging   =2.337. To retain 
at least half of the effe ct of the original treatment, the non- inferiorit y margin is set to
  =0.5∗	   =1.16785 . Due to the fact that in Study 310123 the averaged reader was 
used for evaluation, which helped lowering the variability , the non -inferiority  margin was 
even further lowered to 1.
This means that a 95% two- sided CI for the mean difference BAY 1747846 score –
gadobutrol score must exclude the value -1for non- inferiorit y to be achieved. A one -sided test 
conducted at the 0.025 level of sig nificance would be a statistically  equivalent procedure. The 
null and alternative h ypotheses for non- inferiorit y are:
H :	μBAY	1747846−	μgadobutrol< −1	vs		H :μBAY	1747846−	μgadobutrol≥ −1 ,
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  53of 75
where μBAY	1747846 and μgadobutrol are the mean of the score evaluated by  blinded readers after 
administration of BAY 1747846 and gadobutrol, respectivel y.
The anal yses of the visualization efficacy  variables will be performed on the data from each 
blinded reader, as well as the data obtai ned b y averaging across the 3 blinded readers, 
producing one mean value per participant.
Inter-reader agreement for each of the 3visualization variables will be assessed using the 
intra-class correlation coefficient. Separate coefficients will be generated by  imaging 
modality .
9.4.1.2.2 Lesion Visualization Parameters on Pre-Contrast and Combined Pre-
and Post-Contrast (5 min pi) Images
The anal ysis is based on the data from the blinded readers’ evaluation of the 3 visualization 
parameters, which are evaluat ed in the MRI sets.
A comparison of the pre -contrast and combined pre -and post -contrast images will be 
performed for each of the 3 visualization parameters. Summary  statistics for absolute values 
and difference of the pre- contrast and combined pre -and post -contrast will be presented for 
each Blinded Reader and the Average Reader along with the 95% two -sided CI s for the 
difference of the pre-contrast and combined pre- and post -contrast .
9.4.1.2.3 Number of Lesions on Pre-Contrast and Combine d Pre-and Post-
Contrast (5 min pi) I mages
A table displaying frequencies and percentages of different numbers of  lesions detected by  
pre- and combined pre- and post -contrast will be generated. A CI for the difference in number 
of lesions detected in the two image sets will be constructed.
9.4.1.3 Other Efficacy Analysis
9.4.1.3.1 Efficacy Evaluation at 10and 15min Post Injection
Summary  statistics and frequency  table will additionally  be provided for contrast -enhanced 
images at 10 and 15 min pi.
9.4.1.3.2 Number of Enhanced Lesio ns on Post-Contrast Images at 5min Post 
Injection
A table display ing frequencies and percentages of different numbers of contrast -enhanced 
lesions detected b y BAY 174784 6 and gadobutrol will be generated. A CI for the difference 
in enhanced lesions detect ed by  the 2 study  interventions will be constructed.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  54of 75
9.4.1.3.3 Signal Intensity Measurements
Quantitative measurements will be done in order to evaluate the percentage of lesion 
enhancement in the T1 wsequence after injection of BAY 1747846 or gadobutrol compared to 
the unenhanced T1wsequence. Furthermore, the CNR of the lesions will be determined.
One additional independent blinded reader will perform SImeasurements on the imag e sets. 
The blinded reader will have knowledge if the T1 wsequence is pre -injection or post -injection, 
but will be blinded to knowledge of contrast agent (i.e. BAY 1747846 or gadobutrol). The 
images will be evaluated as follows:
Contrast -enhanced T1 wMRI : the image giving the best visualization of the lesion will 
be chosen (either BAY 1747846 -enhanced or gadobutrol -enhanced sequence). The
region of interest ( ROI) will be placed in that area of the lesion that shows best 
enhancement, avoiding necrotic regions. A second ROI  will be drawn in normal brain 
tissue on the contralateral white matter or in normal spine tissue. A third ROI will be 
positioned in an area outside the brain or spine to determine the background.
All ROI s of the chosen contrast -enhanced sequence will be copied and pasted into the
corresponding images of the other co ntrast -enhanced sequence and the unenhanced
sequence in order to assure same location and size of ROI s in all T1 wimages
(BAY 1747846- enhanced, gadobutrol -enhanced, and unenhanced) .
The percentage of enhancement of the lesion will be based on SImeasurements obtained from
the combined results of unenhanced MRI – BAY 1747846 and unenhanced MRI  –
gadobutrol -enhanced MRI as follows:
SIL,post−SIL,pre
SIL,pre×100%,
where SIL,post is the SI of the contrast -enhanced lesion and SI L,preis the SI of the unenhanced 
lesion. For heterogeneous lesions, multiple ROI s can be placed over different areas, and the 
region that shows the maximum relative enhancement will be u sed for analysis.
SNR and CNR will be calculated based on SI me asurements obtained a s follows:
SNR	=	SIN,post
SDnoise
and
CNR	=	SIL,post−SIN,post
SDnoise,
where SIL,post is the SI of the lesion on the contrast -enhanced image, SIN,post is post injection 
SI of normal tissue of the brain or spine, and SDnoise is the standard deviation of the n oise 
(background).
The ROI size of the same le sion will be identical in all measurements within a single 
participant .SImeasurements will be summarized by  MRI modality  using descriptive statistics 
andCIs.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  55of 75
9.4.2 Safety Analyses
Endpoint Statistical A nalysis Methods
Primary
Not applicable Not applicable
Secondary
Not applicable Not applicable
Other pre -specified
Incidence and severity of TEAEs and other 
parameters
Determine plasma concentrations of Gd within 
3time windows o nDay1 and after 24 ± 4h 
following administration of BAY 1747846 and 
gadobutrolThe number of participants with TEAEs will be 
displayed in a frequenc y table. Descriptive 
results will be displayed for vital signs, ECG 
and safety laboratory.
Individual concentration versus time curv es 
will be provided.
All safet y anal yses will be performed on the SAF popula tion, unless otherwise stated .
9.4.2.1 Adverse Events
Individual listings of AEs will be provi ded.
TEAEs
AEs are considered to be treatment -emergent if they  have started or worsened after first 
application of study  intervention GBCA injection up to 24 h ± 4 h follow -uptime point (i.e. 
per period).
The incidence of TEAEs and study  intervention -related TEAEs, respectively , will be 
summarized by  treatment using Sy stem Organ Class (SOC) and Preferred Terms (PTs) 
according to the current Medical Dictionary  for Regulatory  Activities ( MedDRA )version.
SAEs and D eaths
For SAE outcomes, AEs leading to discontinuation and deaths, listings of participants will be 
provided by treatment sequence, participant and/or AE.
9.4.2.2 Other Safety Examinations
Quantitative data ( hematology , blood chemistry , vital signs ) will be described by  the 
following summary  statistics: arithmetic mea n, standard deviation, minimum, median and 
maximum for quantitative data. These summary  statistics will be presented by  treatment for 
the original data and for the difference to the respective baseline for quantitative data ( i.e.pre-
dose measurements, performed prior to the first administration of the study intervention per 
treatment period). Frequency tables will be provided for qualitative data. Laboratory data 
outside the reference range will be listed and flagged with ‘L’ for low and ‘H’ for high.  
Additional tables with all abnormal (out-of-range) values will be presented.
Graphical display s of individual data and mean values with standard deviations will be 
included.
Data from the standard ECGs will be reported in a descript ive way .
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  56of 75
Pulse oximetry  during MRI  will only  be done for monitoring purposes without documenting 
values within the eCRF. Only  time interval and occurrence of AEs will be documented from 
these measurements.
9.4.2.3 Demographic and Other Baseline Characteristics Analyses
Participant Validity and D isposition
Study  sample size will be summarized by  treatment sequence and total. Participant validity  
with reason for exclusion from anal ysis sets, participant disposition, end of study  medication, 
and important deviations/validity  findings will be summarized by  total using frequency  tables 
over appropriate anal ysis sets like FAS or ‘All enrolled participants’.
Demographics
Summary  statistics (arithmetic mean, standard deviation , median, minimum and maximum for 
quantitative variables) will be presented for all patient s in the analy sis population being 
summarized . Frequency  tables for qualitative data will be provided. If the FAS population 
differ sfrom the SAF population, summary  statistics and frequency  tables for FAS will be 
provided as well.
Medical /Surgical History
The number of participan ts with medical history findings will be summarized by  classified 
data using frequency  tables. The classification will be done according to MedDRA using 
SOC , high level terms and PTs. The most recent MedDRA version will be used.
Prior and Concomitant M edication
The number of participants that used prior or concomitant medication will be anal yzed using 
frequency  tables based on classified data. The classification will be done according to the 
World Health Organization Drug Dictionary (WHO -DD).
9.4.3 Analyses of Gd Plasma C oncentration
Individual Gd p lasma concentrations will be listed per study  intervention (i.e. BAY 1747846 
and gadobutrol). Individual concentration versus time curves of Gd plasma will be provided 
separately  for each treatm ent, for each participant and for all participants.
9.5 Interim Analyses
A non -binding interim analy sis (IA) may  be perfomed for this study to facilitate informed 
planning of the next phases of development. 
The IA can be triggered at an y time when at least 25 participants have been enrolled in a dose 
cohort and have completed both MRI  periods (i.e., at least 50% completion of the dose -
cohort) .
Enrollment in the dose -cohort will continue while the IA is ongoing. Independent of the
outcome from the IA, the cohort will be completed. 
The Statistical Analy sis Plan (SAP) will describe the planned interim anal yses in detail .
In brief, the IA will evaluate the primary  efficacy  endpoint for the selected dose -cohort. 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  57of 75
In case a trend of “no-preference” between BAY 1747846 and gadobutrol ( or a trend of 
“preference of BAY 174846 ”)is observed, further efficacy analyseswill be performed for the 
secondary  endpoint and the number of enhanced lesions .In addition, s afety  analysiswill be 
conducted including the incidence and severity  of TEAEs along with other safet y parameters 
and Gd plasma concentrations. 
If no trend is observed or if deemed inconclusive, no further anal ysis will be performed until 
the primary  completion of the selected dose- cohort.
Since the assessment of the final dose finding algorithm is not based on a formal hy pothesis 
test, the ty pe I error (i.e., the alpha level )will not be adjusted for the IA.
This isa single -blind study and the IAwill not affect the blinding design asonly participants
are blinded and will remain blinded to the sequence of treatment administration. The central 
independent readers evaluating the primary  and secondary  endpoints will remain blinded 
during the IA and the results.
Data wil l be processed and anal yzed by the sponsor and there will not be an independent data 
monitoring committee. The anal ysis will be executed with controlled dissemination to ensure 
the integrit y of ongoing data collection while maintaining sufficient blinding in the study . 
10. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines .
Applicable International Council f or Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines .
Applicable laws and regulations.
The protocol, protocol amendments, I CF, IB, and other relevant documents (e .g.
advertisements) must be submitted to an I RB/IEC by  the investigator and reviewed and 
approved b y the IRB/IEC before the stud y is initiated.
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for chang es necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/IEC .
Notify ing the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  58of 75
Providing oversight of the conduct of the stud y at the study  center and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations .
10.1.2 Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on fin ancial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions 
regard ing the study .
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requir ements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability  and Accountability  Act (HIPAA) requirements, where 
applicable, a nd the IRB/IEC or study  center.
The medical record must include a statement that written informed consent w as 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF.
Participants must be re -consented to the most current version of the IC F(s) during 
their participation in the study .
A cop y of the ICF(s) must be provided to the participant or their legall y authorized 
representative .
Participants who are re -screened are required to sign a new ICF.
If the baseline activities are to be perform ed on the same day  as the ICF is signed, the 
time needs to be documented in addition to the signature date.
10.1.4 Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only ; 
participant names or an y information which would make the participant identi fiable 
will not be transferred.
The participant must be informed that his/her personal study -related data will be used 
by the sponsor in a ccordance with local data protection law. The level of disclosure 
must also b e explained to the participant.
The participant must be informed that his/her medical records may  be examined by  
Clinical QAauditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/IEC members, and b y inspect ors from regulatory  authorities.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  59of 75
10.1.5 Committees Structure
Not applicable.
10.1.6 Dissemination of Clinical Study Data
Result summaries of Bayer's sponsored clinical trials in drug devel opment Phases 2, 3 and 4
and Phase 1 studies in participant s are provided in the Bay er Trial Finder application after 
marketing authorization approval in line with the position of the global pharmaceutical 
industry  associations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition, results of clinical drug 
trials will be provided on the publicly  funded website www.ClinicalTrials.gov and EU 
Clinical Trials Register in line with the applicable regula tions.
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical trials 
in patients for medicines and indications approved in the United States and European Union 
on or after January  01, 2014 as necessary  for conducting legitimate research.
All Bay er sponsored clinical trials are considered for publication in the scientific literature
irrespective of whether the results of the clinic al trials are positive or negative .
10.1.7 Data Quality Assurance
All participant data relating to the stud y will be recorded in the e CRF unless 
transmitted to the sponsor or designee electronically  (e.g.MRI data). The investigator 
is responsible for verify ing that data entries are accurate and correct b y electronicall y 
signing the eCRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.
Data required according to this protocol will be recorded b y investigational site 
personnel via data entry  into the internet -based validated electronic data capture 
(EDC) software s ystem RAVE, which Bay er has licensed from Medidata Solutions 
Worldwide. RAVE has been validated b y Medidata Solutions Worldwide and Ba yer 
for use in its clinical studies. RAVE allows for the application of software logic to set -
up data entry  screens and data checks to ensure the completeness and accuracy  of the 
data entered b y the site personnel. Bayer extensively applies the logic to en sure data 
are complete and reflect the clinical data requirements of the study . Data queries 
resulting from the application of the software logic are resolved b y the site personnel. 
The data are stored at a secure host facility  maintained by  Medidata Solutions 
Worldwide and transferred on a periodic basis to Bay er's internal computer sy stem via 
a secure Virtual Private Network.
All access to the RAVE system is through a password- protected security  system that is 
part of the RAVE software. All internal Bay erand external investigator site personnel 
seeking access must go through a thorough RAVE training process before they  are 
granted access to RAVE for use in Bay er's clinical studies. Training records are 
maintained.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  60of 75
All personnel with access to the RAVE sy stem are supported by  a Service Desk 
staffed with trained personnel to answer questions and ensure access is maintained 
such that data entry  can proceed in a timely  manner.
The RAVE Sy stem contains a sy stem -generated audit trail that captures any changes 
made to a data field, including who made the change, why  the change was made and 
the date and time it was made. This information is available both at the investigator’s 
site and at Bay er. Data entries made in the RAVE EDC screens are supported by 
source docu ments maintained for all participants enrolled in this study .
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Monitoring details describing strategy  (e.g. risk -based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (cen tral, remote, or on -site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
includin g quality checking of the data.
The sponsor assumes accountability  for actions delegated to other individuals (e.g.
Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the eCRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requiremen ts.
Records and documents, inc luding signed ICFs, pertaining to the conduct of this study  
must be retained b y the investigator for 15years after study  completion unless local 
regulations or institutional policies require a longer retention period. No records may  
be destro yed during th e retention period without the written approval of the sponsor. 
No records may  be transferred to another location or part y without writt en notification 
to the sponsor.
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data entered in the eCRF that are transcribed from source documents must be 
consis tent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available.
Definiti on of what constitute s source data can be found in the investigator site file.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  61of 75
10.1.9 Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been collected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the prot ocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines .
Inadequate recruitment of participants by  the investigator.
Discontinuation of further study  intervention development .
10.1.10 Publication Policy
The re sults of this study  may  be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary  infor mation and t o 
provide comments.
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publication of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordinating investigator will be designated b y mutual 
agreement.
Authorship will be determined by  mutual agreement and in line with I nternational 
Committee of Medical Journal Editors authorship requirements.
10.2 Appendix 2: Clinical Laboratory Tests
Blood and urine sampling for laboratory  anal ysis will be taken as outlined in the SoA 
(see Section 1.3).
The tests detailed in Table 10-1will be performed by  local laboratories or the central 
laboratory .
Protocol -specific requirements for inclusion or exclusion of participants are detailed i n 
Section 5of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by the investigator or required by  local regulations.
Urine p regnancy  testing will be performed before each administration of study  
intervention to evaluate eligibility  of female participants (see Section 5.2 criterion 14).
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  62of 75
Table 10-1: Parameters of laboratory analyses
Parameters (by category) Sample destination
Blood / Plasma / Serum 
Hematology:
Leukocytes, er ythroc ytes, hemoglobin, hematocrit, mean corpuscular 
volume, mean corpuscular hemoglobin, platelets, neutrophils, eosinophils, 
basophils, ly mphocytes, monocytesLocal laboratory
Serum chemistry:
Alanine aminotransferase, aspartate aminotransferase, gamma -glutam yl 
transferase, alkaline phosphatase, total bilirubin, lactate dehydrogenase, 
creatinine, urea, creatine kinase, chloride, potassium, sodium, calcium, 
phosphate, glucose, total protein, albumin, hig h-sensitivity C -reactive 
proteinLocal laboratory
Creatinine Central laboratory
Plasma concentration :
BAY 1747846Central laboratory
Urine
Urinalysis –dipstick (spot urine):
pH value, urobilinogen, erythrocytes/hemoglobin, leukocy tes, protein, 
ketone, bilirubin, nitrite, glucoseLocal laboratory
Sediment (spot urine) :
Only in case of abnormal urinalysis results for protein, leukocy tes, 
erythroc ytes/ hemoglobin, or nitriteLocal laboratory
Pregnancy test (spot urine) before administration of study 
interventionTo be performed at 
study site
Investigators must document their review of each laboratory  safet y report.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  63of 75
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
after providing written informed consent, whether or not considered related to the 
study  intervention . 
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) associated 
with the use of study  intervention.
Events Meeting the AE Definition 
Any abnormal laboratory test results (h ematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (e .g.ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming int ent. Such overdoses should be reported re gardless of sequelae.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (e .g.endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  64of 75
10.3.2 Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c. Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay ) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any  other serious c riteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not conside red an AE.
d. Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
signifi cance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e .g.sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but may  
jeopardize the participant or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These events should usually  
be considered serious.
Examples of such events include invas ive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  65of 75
10.3.3 Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e .g.hospital progress notes, laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then re cord all relevant AE/SAE information in the eCRF.
It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to the sponsor in lieu of completion of the AE/SAE eCRF page.
There may  be instances when copies of medical records for certain cases are 
requested b ythe sponsor . In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copies of the medical records 
before submission to the sponsor.
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE 
reported during the stud y and assign it to 1 of the following categories:
Mild: An event that is easily  tolerated by  the participant, causing 
minimal discomfort and not interfering with every day activit ies.
Moderate: An event that causes sufficient discomfort and interferes with 
normal every day activities.
Severe: An event that prevents normal every day activities. An AE that 
is assessed as severe should not be confused with an SAE. Severe is a 
category  utilized for rating the intensit y of an event; and both AEs and 
SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT wh en it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence,
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  66of 75
The investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to includ e in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Important factors to be considered in assessing the relationship of the AE to study  
intervention include:
The temporal sequence from study  intervention administration: The event should 
occur after the stud y intervention is given. The length of time from stud y 
intervention exposur e to event should be evaluated in the clinical context of the 
event.
Underl ying, concomitant, intercurrent diseases: Each event should be evaluated in 
the context of the natural history  and course of the disease being treated and any  
other disease the part icipant may  have.
Concomitant medication or treatment: The other drugs the participant is taking or 
the treatment the participant receives should be examined to determine whether 
any of them might have caused the event in question.
Known response pattern f or this class of drug: Clinical/preclinical.
Exposure to phy sical and/or mental stresses: The exposure to stress might induce 
adverse changes in the recipient and provide a logical and better explanation for 
the event.
The assessment is not possible.
Causal relationship to protocol -required procedures
The assessment of a possible causal relationship between the AE and protocol -required 
procedure(s) is based on the question whether there was a ‘reasonable causal relationship’ 
to protocol -required procedure(s ).
Possible answers are “y es” or “no”.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  67of 75
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by the 
sponsor to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.
If a particip ant dies during participation in the study  or during a recognized follow -
up period, the investigator will provide the sponsor with a cop y of an y post mortem
findings including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hof 
receipt of the information.
10.3.4 Reporting of SAEs
SAE Reporting to the sponsor via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to the sponsor will be the EDC tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 h.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the EDC tool will be taken off -line to 
prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the EDC tool has been taken off -line, then 
the site can report this information on a paper SAE form (see next section) or to the 
sponsor by telephone.
Contacts for SAE reporting can be found in the investigators site file.
SAE Reporting to the sponsor via Paper CRF
Facsimile transmission of the SAE paper CRF or provision of related PDF scans via 
email is the preferred method to transmit this information to the sponsor .
In rare circumstances and in the absence of facsimile and PDF/email equipment, 
notification by  telephone is acceptable with a copy  of the SAE data col lection tool 
sent by  overnight mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the investigators site file.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  68of 75
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Contraception Guidance
For the purpose of this guidance, methods that can achieve a failure rate of less than 1% per
year when used consistently  and correctly  are considered as highl y effective birth contro l
methods. Such methods include:
combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation:
ooral
ointravaginal
otransdermal
progestogen-onl y hormonal contraception associated with inhibition of ovulation:
ooral
oinjectable
oimplantable 
intrauterine device (IUD) 
intrauterine hormone -releasing s ystem (IUS)
bilateral tubal occlusion 
vasectomized partner 
sexual abstinence 
In addition, m aleparticipants with partners of childbearing potential should use a condom
from screening till end of study  participation.
Collection of Pregnancy Information
Male Participants with Partners Who Become Pregnant
The investigator will attempt to collect pregnancy  information on any  male 
participant’s female partner who beco mes pregnant while the male participant is in 
this study . This applies only  to male participants who receive d study  intervention .
After obtaining the necessary  signed ICF from the pregnant female partner directly , 
the investigator will record pregnancy  information on the appropriate form and submit 
it to the sponsor within 24h of learning of the partner’s pregnancy . The female partner 
will also be followed to determine the outcome of the pregnancy . Information on the 
status of the mother and child will be forwarded to the sponsor. Generall y, the follow-
up will be no longer than 6 to 8 weeks following the estimated delivery  date. Any  
termination of the pregnancy  will be reported regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  69of 75
Female Participants Who Become Pregnant 
The investigator will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. I nformation will be recorded on 
the appropriate form and submitted to the sponsor within 24 h o f learning of a 
participant's p regnancy .
The participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on the participant and the neonate , after 
obtaining the si gned ICF from both parents, unless local law or specific circumstances 
of the respective case allow otherwise, and the information will be forwarded to the 
sponsor. Generally , follow -up will not be required for longer than 6 to 8 weeks bey ond 
the estimated delivery  date. Any  termination of pregnancy  will be reported, regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or electiv e termination of a pregnancy  will be reported as an AE or SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such. An y post -study  pregnancy  related SAE considered reasonabl y related to the 
study  intervention b y the invest igator will be reported to the sponsor as described in 
Section8.3.4 . While the investigator is not obligated to activel y seek this information 
in former stud y part icipants, he or she may  learn of an SAE through spontaneous 
reporting.
Any female participant who becomes pregnant while participating in the study  will be 
withdrawn from the study.
10.5 Appendix 5: Abbreviations
2/3D 2/3 dimensional
AE adverse event
AESI adverse event of special safet y interest
AUC area under the concentration versus time curve from zero to infinity  after 
single (first) dose
AUC norm AUC normalized for dose and bod y weight
BMI body  mass index
BP blood pressure
bw body  weight
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CL total body  clearance of drug
CL/bw total body  clearance of drug normalized by  body  weight
Cmax maximum observed drug concentration in measured matrix after single dose 
administration
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  70of 75
CNR contrast to noise ratio
CNS central nervous s ystem
CONSORT Consolidated Standards of Reporting Trials
COVID -19 coronavirus disease 2019
CV coefficient of variation
d day(s)
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
FAS full analy sis set
FDA U.S. Food and Drug Administration
FiH first-in-human
FLAIR Fluid Attenuated Inversion Recovery
GBCA gadolinium -based contrast agent
GCIS General Clinical I maging Services
GCP Good Clinical Practice
Gd gadolinium 
GFR glomerular filtration rate
GRE gradient recalled echo
HIPAA Health Insurance Portability  and Accountability  Act
HR heart rate
IA Interim anal ysis
IB Investigator’ s Brochure
ICF informed consent form
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
IEC Independent Ethics Committees
IMP investigational medicinal product
IR inversion recovery
IRB Institutional Review Boards
IV intravenous(l y)
MedDRA Medical Dictionary  for Regulatory  Activities
MR magnetic resonance
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  71of 75
MRI magnetic resonance imaging
NEX number of excitations
NIMP non-investigational medicinal product
NSA number of acquisitions
NSF Nephrogenic S ystemic Fibrosis
PDF Portable Document Format
pH pondus hydrogenii (negative log of the ion concentration)
pi post injection
PK pharmacokinetic(s)
PR PR interval
PT preferred term
QA quality  assurance
QC quality  control
QRS QRS interval in ECG
QT QT interval in ECG, uncorrected
QTc QT corrected b y heart rate
ROI region of interest
RSE relative signal enhancement
SAE serious adverse event
SAF safet y analysis set
SAP Statistical Analy sis Plan
SE spin echo
SI signal intensity
SmPC Summary  of Product Characteristics
SNR signal to noise ratio
SoA Schedule of Activities
SOC system organ class
SUSAR suspected unexpected serious adverse reactions
T1W T1-weighted
TE echo time
TEAE treatment -emergent adverse event
TI inversion time
TR repetition time
Vss volume of distribution at steady  state
Vss/bw Vssnormalized by  body  weight
C O N FI D E N TI A L I nte grate d Cli nical St u d y Pr ot oc ol 
BA Y 1 7 4 7 8 4 6 / 2 0 2 4 1 
0 6 J A N 2 0 2 2 Pa ge:  7 2 of 7 5 
1 0. 6 A p pe n di x 6: Pr ot oc ol A me n d me nt Hist or y 
T he Pr ot oc ol A me n d me nt S u m mar y  of C ha n ges Ta ble f or t he c urre nt a me n d me nt is l ocate d 
directl y  bef ore t he Ta ble of C o nte nts ( T O C). 
A m e n d me nt 3 ( 2 9 J U L 2 0 2 1) 
T his a me n d me nt is c o nsi dere d t o be s u bsta ntial base d o n t he criteria set f ort h i n Article 1 0(a) 
of Directi ve 2 0 0 1/ 2 0/ E C of t he E ur o pea n Parlia me nt a n d t he C o u ncil of t he E ur o pea n U ni o n. 
O ver all R ati o n ale f or t he A me n d me nt: 
T his a me n d me nt was pri maril y i m ple me nte d t o i nc or p orate a n i nteri m a nal y sis t o facilitate 
t he pla n ni n g of f ut ure p hases of de vel o p me nt a n d u pc o mi n g e n d of P hase 2meeti n gs 
/scie ntific a d vis or y  disc ussi o ns wit h Healt h A ut h orities . T he descri pti o n of c ha n ge sa n d a 
brief rati o nale f or eac h c ha n ge are as f oll o ws: 
S e cti o n # 
a n d N a m e D e s cri pti o n of C h a n g e Bri ef R ati o n al e 
Title Pa ge Up date of me dicall y res p o nsi ble 
pers o n f or t he st u d y .I n or der t o mai ntai n c o nsiste nc y 
wit h t he u p date d i nter nal cli nical 
pr ot oc ol te m plate. T he rele va nt 
c o ntact na me a n d r ole (  
) f or all rele va nt 
me dicall y relate d q ueries a n d safet y 
re p orti n g re q uire me nts is 
mai ntai ne d. 
Title Pa ge 
D oc u me nt Hist or y Ta ble 
Hea der t hr o u g h o ut T he v er si o n n u m ber has bee n a d de d t o 
title pa ge, D oc u me nt Hist or y Ta ble 
has bee n i nc or p orate d as a n 
i n de pe n de nt secti o n, a n d t he d oc u me nt 
hea der has bee n m o difie d t hr o u g h o ut 
t o re m o ve versi o n n u m ber a n d i ncl u de 
t he versi o n date .U p date d t o reflect c urre nt i nter nal 
pr ocesses a n d pr ot oc ol te m plate 
c o n ve nti o ns. 
1. 3 Sc he d ule of Acti vities 
5. 1 I ncl usi o n Criteria T he S o A a n d i ncl usi o n criteri o n # 6 
were u p date d t o f urt her clarif y t hat 
w hile baseli ne e G F R val ue ≥6 0 
m L/ mi n/ 1. 7 3 m 2is re q uire d pri or t o 
a d mi nistrati o n of st u d y i nter ve nti o n, 
t he baseli ne e G F R assess me nt f or 
peri o d 1 ca n be deri ve d fr o m a ser u m 
creati ni ne res ult o btai ne d w it hi n 4 
wee ks pri or t o t he first M RI .As ser u m 
creati ni ne is a n i ncl u de d para meter f or 
safet y la b o rat or y assess me nts, t he 
safet y bl o o d sa m ple c ollecte d at 
baseli ne ( wit hi n 4 8 h o urs pri or t o 
a d mi nistrati o n of st u d y i nter ve nti o n), 
ca n als o be utilize d f or deter mi nati o n 
of e G F R f or eit her c orres p o n di n g 
peri o d. Clarificati o n of pr oce d ures 
pertai ni n g t o ba seli ne e G F R 
assess me nts i n t he S o A a n d 
i ncl usi o n criteri o n # 6. P P D 
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  73of 75
Section # 
and NameDescription of Change Brief Rationale
5.2 Exclusion Criteria Exclusion criterion #12 w as updated to 
include consideration of the half -life 
of anyprevious investigational drug 
and clarify eligibility of participants 
that would be in the follow -up period 
of another trial while not receiving 
investigational drug . 
Exclusion criterion #13 w as updated to 
clarify that contraindications 
pertaining to the administration of 
gadobutrol w ill be interpreted based 
on the local product label.Exclusion criterion #12 w as 
updated in order to provide 
additional flexibility with prior 
clinical trial participation and with 
respect to facilitating recruitment of 
participants who are in the follow -
up period of concurrent studies but 
are not receiving investigational 
drug. 
The local product label may vary 
depending on the location of the 
study site.
6.1 Study Interventions 
AdministeredTable 6 -1 was modified to reflect the 
addition of Bulgaria as a study 
country. Study sites are currently being 
established in an additional country 
(Bulgaria), thus Bulgaria has been 
added to the protocol.
8.1.4.3 Number of 
Enhanced LesionsRevised text to specify thatthe 3 
blinded readers will record the total 
number of enhanced lesions for each 
enhanced (5 min pi)MR image set 
separately (no matched pairs 
approach). Correction of previous error 
indicating  4 to 5 min pi for 
recorded number of enhanced 
lesions per MR image set. 
8.2.6 Clinical Safety 
Laboratory Assessments
8.5.1 Drug MeasurementsSpecification of laboratory manual as 
primary guidance document for study 
samples. References to the sample 
handling sheets were removed .Information about the collection, 
processing, storage and shipment of 
laboratory samples is provided in 
the laboratory manual.
9.4.2.2 Other Safety 
ExaminationsThe text pertaining to standard ECG 
data w as revised to remove the 
requirement that they only be listed.The requirement to only list 
standard ECG data w as rem oved to 
provide greater flexibility with 
respect to t he descriptive statistical 
output provided.
9.5 Interim Analyses
10.5 AbbreviationsAddition of an interim analysis.
Abbreviations for interim analysis 
(IA) and Statistical Analysis Plan 
(SAP) w ere added accordingly.An interim analysis of the dose 
inves tigated, as well as some 
selected efficacy and safety data
will facilitate the planning offuture 
phases of development and 
upcoming end of Phase 2 meetings
/scientific advice with Health 
Authorities.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  74of 75
11. References
Bayer Vital GmbH, Leverkusen. SmPC of Gadovist 1.0 mmol/ml solution for injection . 
November 2017. Available at: https://www.medicines.org.uk/emc/product/2876/smpc
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, 
Gerstner E, Alexander B, Goldmacher G, Wick W, et al. Consensus recommendations for a 
standardized Brain Tumor I maging Protocol in clinical trials. Neuro l Oncol 2015; 17(9) :1188-
1198 .
European Medicines Agency . PRAC confirms restrictions on the use of linear gado linium 
agents. EMA/424715/2017. A vailabl e at: 
https://www.ema.europa.eu/documents/referral/gadolinium- article -31-referral -prac-confirms -
restrictions- use-linear -gadolinium -agents_en.pdf .
FDA Guidance “Non -Inferiority  Clinical Trials to Establish Effectiveness”. November 2016. 
Available at: 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/non -inferiority -
clinical -trials
Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing 
dermopath y and nephrogenic systemic fibrosis? Nephrology Dial ysis Transplantation.
2006;21:1104-8.
Guerbet LLC USA. SmPC of Dotarem. August 2017. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204781s001lbl.pdf
Investigator ’s Brochure of BAY 1747846, version 3.0 (dated 31 Jan 20 20).
Kanal, E. Gadolinium based contrast agents (GBCA): safet y overview after 3 decades of 
clinical experience. Magnetic Reson I maging. 2016;34(10):1341–5.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity  in the dentate 
nucleus and globus pall idus on unenhanced T1 -weighted MR images: relationship with 
increasing cumulative dose of a gadolinium based contrast material. Radiology . 
2014;270(3):834 –41.
Le Mignon M M, Chambon C, Warrington S, Davies R, Bonnemain B. Gd -DOTA: 
Pharmacokinetics and toler ability  after intravenous injection into Healthy  Volunteers. Invest. 
Radiol. 1990;25:933 -937.
Nonclinical Research Report PH- 40545 (study  number KM17051): Three -phase liver and 
steady -state head MRI with BAY 1747846 in minipigs. 2018 .
Prince MR, Zhang H, Z ou Z, Staron RB, Brill PW. I ncidence of immediate gadolinium 
contrast media reactions. AJR Am J Roentgenol. 2011;196(2):196:W138 –43.
Radbruch A. Are some agents less likel y to deposit gadolinium in the brain? Magn Reson 
Imaging. 2016;34(10):1351 –4.
CONFIDENTIAL Integrated Clinical Study Protocol
BAY1747846 / 20241
06 JAN 2022 Page:  75of 75
Report A44213 (Study No. 13226): Exploratory  population pharmacokinetic anal ysis of 
gadobutrol (Gadovist®), to assess ethnic differences between Japanese and Caucasian healthy 
volunteers . 2008 .
Report A47567 (Study  No. 310123): A multicenter, randomized, double-b lind, crossover, 
phase 3 study  to determine the safety  and efficacy of gadobutrol 1.0 molar (Gadovist®) in 
patients referred for contrast -enhanced MRI of the central nervous s ystem (CNS). 2010.
Report No. 9746 (Study  No. 92001): Tolerability  and pharmacoki netics of gadobutrol (SH L 
562 A) after intravenous administration in comparison with placebo (first in man 
administration) . 1994 .
Runge VM. Safet y of the gadolinium -based contrast agents for magnetic resonance imaging, 
focusing in part on their accumulati on in the brain and especially the dentate nucleus. Invest 
Radiol. 2016;51(5):273–9.
Scott 2018. Gadobutrol: A Review in Contrast -Enhanced MRI and MRA. Clin Drug Investig.
2018 Aug;38:773 -784.